Protein complexes comprising oxime- or hydrazone-coupled peptides and methods of using
Protein complexes with oxime or hydrazone-linked epitopes on MHC scaffolds address the lack of specificity in immunotherapies, enabling targeted T cell activation and reducing side effects by leveraging the unique TCR-MHC interaction.
Patent Information
- Application Number
- PCT/US2026/027017
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current immunotherapies lack specificity, leading to undesirable side effects such as hyperactive immune responses and toxicity due to indiscriminate targeting of all T cells, as they stimulate signaling through the TCR complex or costimulatory molecules that are identical in all T cells.
Development of protein complexes comprising MHC scaffolds with epitopes coupled to beta2m polypeptides via oxime or hydrazone linkages, allowing specific regulation of T cells by targeting the unique interaction between TCR and MHC/peptide complexes.
The solution enables specific activation and regulation of T cells, reducing side effects and enhancing therapeutic efficacy by targeting only the relevant T cells, while being compatible with peptides with post-translational modifications and unnatural amino acids.
Smart Images

Figure US2026027017_12112026_PF_FP_ABST
Abstract
Description
PROTEIN COMPLEXES COMPRISING OXIME- OR HYDRAZONE-COUPLED PEPTIDES AND METHODS OF USINGCROSS REFERENCE TO RELATED APPLICATION
[0001] This International Patent Application claims priority to U. S. Provisional Application No. 63 / 802,926, filed on May 9, 2025, which is hereby incorporated by reference in its entirety.REFERENCE TO A SEQUENCE LISTING
[0002] This application contains a Sequence Listing, which has been submitted electronically in xml format and is hereby incorporated by reference in its entirety. Said xml copy, created on May 1, 2026, is named SeqList-182219-00303.xml and is 79,072 bytes in size.FIELD
[0003] The present disclosure relates generally to the field of molecular biology and medicine. More particularly, the methods and compositions herein are useful for treating disease.BACKGROUND
[0004] Many immunotherapies for the treatment of infection or cancer work by regulating T cell activity in vivo. At the core of the molecular events underlying these therapies is the engagement of the T cell receptor (TCR) with a small peptide antigen non-covalently presented by a major histocompatibility complex (MHC) molecule. Following epitope-specific cell targeting, the recruited T cells can be activated through general engagement of costimulatory molecules found on the antigen-presenting cell as well as by cytokines produced by a range of immune cells. These signals (peptide presentation, co-stimulation, and cytokine signaling) are utilized to drive T cell specificity, activation, differentiation, and durability. During T cell development, a genomic editing process results in the expression of a unique TCR on every T cell, while a costimulatory molecule, such as CD28, is generally expressed on all T cells (or large T cell subsets) and cytokines, such as IL-2, are provided by a variety of immune cells.
[0005] Current immunotherapies often lack specificity since many approaches stimulate signaling through the TCR complex by binding the CD3 complex, which is identical in all T cells, and / or signaling through costimulatory molecules, etc., resulting in '‘global therapies’’. While these global immunotherapies can be extremely potent, they indiscriminately target all185193632 1T cells. As such, existing approaches can lead to undesirable side effects such as a hyperactive immune response and significant toxicity.
[0006] Accordingly, provided herein are therapies that take advantage of the uniquely specific interaction between a TCR and an MHC / peptide complex, allowing the specific regulation of the specific T cells of interest in vivo.SUMMARY
[0007] Provided herein are MHC scaffolds and protein complexes as well as methods of using them.
[0008] Provided is a protein complex comprising: (a) a major histocompatibility (MHC) complex comprising (i) a class I major histocompatibility (MHC) heavy chain or a fragment, variant, or derivative thereof, and (ii) a beta 2 microglobulin (beta2m) polypeptide or a fragment, variant, or derivative thereof; and (b) an epitope; wherein the epitope is coupled to the N-terminus of the beta2m polypeptide or the fragment, variant, or derivative thereof via an oxime or hydrazone linkage.
[0009] In one embodiment, the protein complex further comprises a first linker between the epitope and the oxime or hydrazone linkage. In some embodiments, the first linker is a polypeptide linker or an amino acid polymer hybrid.
[0010] In some embodiments, the MHC heavy chain comprises a human class I MHC polypeptide derived from HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, or HLA-G. In some embodiments, the MHC heavy chain comprises a human class I MHC polypeptide derived from an HLA-A, HLA-B, HLA-C, HLA-D, HLA-E. HLA-F, or HLA-G allele. In some embodiments, the MHC heavy chain comprises a human class I MHC polypeptide derived fromHLA-A*02:01 orHLA-C*03:04. In some embodiments, the MHC heavy chain comprises a murine class I MHC polypeptide derived from H-2K, H-2D, H-2L, H-2Q, H-2M, or H-2T. In some embodiments, the MHC heavy chain comprises a simian class I MHC polypeptide derived from an A, B, or C, E, F, or G gene. In one embodiment, the MHC heavy chain comprises a canine class I MHC polypeptide derived from DLA-I. In some embodiments, the MHC heavy chain comprises a sequence that is at least 80% identical to any one of SEQ ID NOs:16-18. In some embodiments, the MHC heavy chain comprises any one of SEQ ID NOs: 16-18.2185193632.1
[0011] In some embodiments, the beta2m polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO:21 or SEQ ID NO:22. In some embodiments, the beta2m polypeptide comprises SEQ ID NO:21 or SEQ ID NO:22. In one embodiment, the MHC heavy chain or the fragment, variant, or derivative thereof comprises an internal disulfide bond. In one embodiment, the MHC heavy chain or the fragment, variant, or derivative thereof comprises an internal disulfide bond that comprises a disulfide bond between residues 84C and 139C, numbered relative to any one of SEQ ID NOs: 16-18. In one embodiment, the MHC heavy chain or the fragment, variant, or derivative thereof is connected to the beta2m polypeptide or the fragment, variant, or derivative thereof via a disulfide bond. In one embodiment, the MHC heavy chain or the fragment, variant, or derivative thereof comprises an alphal, alpha2, and alpha3 chain, and wherein the alpha3 chain and the beta2m polypeptide or the fragment, variant, or derivative thereof are connected via the disulfide bond. In some embodiments, the disulfide bond connecting the alpha3 chain and the beta2m polypeptide or the fragment, variant, or derivative thereof is between residue 236C of the MHC heavy chain or the fragment, variant, or derivative thereof (numbered relative to SEQ ID NO: 16 or SEQ ID NO: 18) and residue 12C of the beta2m polypeptide or the fragment, variant, or derivative thereof (numbered relative to SEQ ID NO: 21).
[0012] In one embodiment, the protein complex further comprises a second linker between the N-terminal amino acid of the beta2m polypeptide or the fragment, variant, or derivative thereof and the remainder of the beta2m polypeptide or the fragment, variant, or derivative thereof. In one embodiment, the second linker is a polypeptide linker.
[0013] In one embodiment, the protein complex further comprises a fragment crystallizable (Fc) domain.
[0014] In one embodiment, the N-terminus of the Fc domain is connected to the C-terminus of the MHC heavy chain or the fragment, variant, or derivative thereof via a third linker. In one embodiment, the third linker is a polypeptide linker.
[0015] In some embodiments, the protein complex further comprises one or more co-modulatory domains. In some embodiments, the one or more co-modulatory domains are selected from the group consisting of a CD28 agonist, IL-15, or IL-2. In some embodiments, at least one of the one or more co-modulatory domains comprises a sequence that is at least 80% identical to any one of SEQ ID NOs:23-27. In some embodiments, at least one of the one or more co-modulatory domains comprises any one of SEQ ID NOs:23-27.3185193632.1
[0016] In some embodiments, the protein complex comprises at least two co-modulatory domains and wherein the two co-modulatory domains are connected to each other via a fourth linker. In one embodiment, the fourth linker is a polypeptide linker.
[0017] In some embodiments, the one or more co-modulatory domains are connected to (1) the C-terminus of the beta2m polypeptide or the fragment, variant, or derivative thereof or (2) the N-terminus of the MHC heavy chain or the fragment, variant, or derivative thereof via a fifth linker. In one embodiment, the fifth linker is a polypeptide linker.
[0018] In one embodiment, the MHC heavy chain or the fragment, variant, or derivative thereof and the beta2m polypeptide or the fragment, variant, or derivative thereof are part of a continuous amino acid chain. In one embodiment, the MHC heavy chain or the fragment, variant, or derivative thereof, and the beta2m polypeptide or the fragment, variant, or derivative thereof are connected through a sixth linker. In one embodiment, the sixth linker is a polypeptide linker.
[0019] In one embodiment, the one or more co-modulatory domains are connected to the C-terminus of the Fc domain.
[0020] In some embodiments, the polypeptide linker predominantly comprises glycines, serines, and / or alanines. In some embodiments, the polypeptide linker comprises any one of SEQ ID NOs:28-37.
[0021] In some embodiments, the epitope is 5 to 20 amino acids long. In some embodiments, the epitope is derived from a polypeptide from a bacterial, viral, fungal, protozoan, or multicellular organism. In some embodiments, the epitope is derived from a cytomegalovirus (CMV) polypeptide, a human immunodeficiency virus (HIV) polypeptide, a SARS-CoV-2 virus polypeptide, or a hepatitis virus polypeptide. In some embodiments, the epitope comprises a sequence derived from CMV pp65, HIV gag, HIV reverse transcriptase, or SARS-CoV-2 spike protein. In some embodiments, the epitope comprises any one of SEQ ID NO:39, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ IDNO:60, or SEQ IDNO:61. In some embodiments, the epitope is a cancer antigen or fragment thereof. In some embodiments, the cancer antigen is melanoma antigen recognized by T cells I (MART-1). In some embodiments, the epitope is an autoimmune epitope or fragment thereof. In some embodiments, the autoimmune epitope is preproinsulin, or islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP).4185193632.1
[0022] Provided is a pharmaceutical composition comprising (a) a protein complex disclosed herein and (b) a pharmaceutically acceptable excipient.
[0023] Provided is a method of activating a T cell comprising a TCR, the method comprising contacting the T cell with: (a) a protein complex disclosed herein; or (b) a pharmaceutical composition comprising a protein complex disclosed herein and a pharmaceutically acceptable excipient; wherein the TCR of the T cell binds to the epitope.
[0024] Provided herein is a method of inducing expression of pro-inflammatory cytokines in a T cell comprising a TCR, the method comprising contacting the T cell with: (a) a protein complex disclosed herein; or (b) a pharmaceutical composition comprising a protein complex disclosed herein and a pharmaceutically acceptable excipient; wherein the TCR of the T cell binds to the epitope.
[0025] Provided is a method of expanding a population of T cells or NK cells, each comprising a TCR, the method comprising contacting the population of T cells with: (a) a protein complex disclosed herein; or (b) a pharmaceutical composition comprising a protein complex disclosed herein and a pharmaceutically acceptable excipient, wherein the TCR of the T cells binds to the epitope.
[0026] Provided is a method of inducing killing of a cell infected by a pathogen, wherein the cell displays on its surface a polypeptide derived from the pathogen, the method comprising: contacting a population of T cells with a protein complex disclosed herein or with a pharmaceutical composition comprising a protein complex disclosed herein and a pharmaceutically acceptable excipient, thereby generating a population of activated T cells, wherein each T cell comprises a TCR, wherein the TCR is capable of binding to the polypeptide derived from the pathogen and to the epitope: and exposing the cell infected by the pathogen to the population of activated T cells.
[0027] Provided is a method of inducing killing of a cancer cell, wherein the cancer cell displays on its surface a cancer antigen, the method comprising: contacting a population of T cells with a protein complex disclosed herein or with a pharmaceutical composition comprising a protein complex disclosed herein and a pharmaceutically acceptable excipient, thereby generating a population of activated T cells, wherein each T cell comprises a TCR, wherein the TCR is capable of binding to the cancer antigen and to the epitope; and exposing the cancer cell to the population of activated T cells.5185193632.1
[0028] In some embodiments, the population of activated T cells is further expanded before step (b).
[0029] Provided is a method of treating an infection with a pathogen in a subject in need thereof, the method comprising administering to the subject a protein complex disclosed herein or a pharmaceutical composition comprising a protein complex disclosed herein and a pharmaceutically acceptable excipient, wherein: the subject has a cell that displays on its surface a polypeptide derived from the pathogen; and the subject has a T cell that comprises a TCR, wherein the TCR is capable of binding to the polypeptide derived from the pathogen and to the epitope.
[0030] Provided is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a protein complex disclosed herein or a pharmaceutical composition comprising a protein complex disclosed herein and a pharmaceutically acceptable excipient, wherein: the subject has a cancer cell that displays on its surface a cancer antigen; and the subject has a T cell that comprises a TCR, wherein the TCR is capable of binding to the cancer antigen and to the epitope.
[0031] Provided is a method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject a protein complex disclosed herein or a pharmaceutical composition comprising a protein complex disclosed herein and a pharmaceutically acceptable excipient, wherein the subject has a T cell that comprises a TCR, wherein the TCR is capable of binding to the autoimmune peptide and to the epitope, and wherein the one or more co-modulatory domains are inhibiting co-modulatory domains.
[0032] In one embodiment, the subject is a mammal, preferentially a human.
[0033] Provided is a method of making a protein complex comprising (a) an MHC complex comprising (i) a class I MHC heavy chain or a fragment, variant, or derivative thereof, and (ii) a beta2m polypeptide or a fragment, variant, or derivative thereof and (b) an epitope, the method comprising: (a) oxidizing the N-terminal amino acid of the beta2m polypeptide or the fragment, variant, or derivative thereof, to form an aldehyde at the N-terminal position of the beta2m polypeptide or the fragment, variant, or derivative thereof, wherein the N-terminal amino acid is serine or threonine; (b) reacting the aldehyde formed in step (a) with a primary amine catalyst to form a Schiff base; and (c) reacting the Schiff base formed in step (b) with an epitope comprising a functional group comprising an alkoxyamine, a hydrazino, or a hydrazide to form the protein complex, wherein in the protein complex, the epitope is coupled 6185193632.1to the N-terminus of the beta2m polypeptide or the fragment, variant, or derivative thereof via an oxime or a hydrazone linkage.
[0034] In some embodiments, the functional group comprising an alkoxyamine is selected from the group consisting of:
[0035] In some embodiments, the functional group comprising a hydrazino or hydrazide is selected from the group consisting of:
[0036] In one embodiment, the protein complex further comprises a seventh linker between the epitope and the functional group. In some embodiments, the seventh linker is a polypeptide linker or a polyethylene glycol linker.
[0037] In some embodiments, in step (a), the N-terminal amino acid on the beta2m polypeptide or fragment, variant, or derivative thereof is reacted with an oxidizing agent selected from the group consisting of sodium periodate (NaIO4), and potassium perruthenate (KRuO4). In some embodiments, steps (b) and (c) are performed consecutively in the same reaction vessel without isolation of the Schiff base formed in step (b). In one embodiment, the primary amine catalyst is an aniline derivative. In some embodiments, the primary amine catalyst is selected from the group consisting of benzamide, phenylene diamine, o-toluidine, m-toluidine, p-toluidine, o-anisidine, m-anisidine, and p-anisidine.BRIEF DESCRIPTION OF THE FIGURES
[0038] Fig. 1 shows the structure of an illustrative protein complex disclosed herein. (1) An antigenic peptide is covalently tethered to beta2m via an oxime or hydrazone linkage, optionally, via glycine-rich linkers. (2) An MHC Class I module comprises an alpha chain with three domains (alphal, alpha2 and alpha3) and a beta2m chain. The MHC may be stabilized by (1) an internal disulfide bond and / or (2) a disulfide bond between beta2m and the alpha3 domain of the heavy chain and / or (3) by a disulfide between the alpha3 domain of the heavy 7185193632.1chain and the linker joining the antigenic peptide and beta2m. (3) Co-modulatory domain. (4) Fc segment.
[0039] Fig. 2 shows a protein complex with an antigenic peptide and an MHC scaffold without the antigenic peptide. Left panel: In a protein complex, an antigenic peptide is covalently linked to the N-terminus of beta2m, for example, via a (G4S)5linker, to the recombinant MHC scaffold. Right panel: An empty MHC scaffold is expressed without the antigenic peptide. An (optional) engineered disulfide bond within the MHC heavy chain can allow for stabilization in the absence of peptide. An engineered N-terminal residue, such as a serine or threonine, allows for the covalent attachment of the antigenic peptide to the beta2m domain using aldehyde-alkoxyamine or aldehyde-hydrazino / hydrazide chemistry.
[0040] Fig. 3 illustrates different, non-limiting, protein complex designs. Expression of empty MHC scaffolds based on HLA-A2 with (1) no co-modulatory domain (MOD), (2) an IL-2 co-modulatory domain, (3) an IL-15 / Ralpha co-modulatory domain, and (4) an CD28 agonist scFv co-modulatory domain. Left panel: Reducing SDS-PAGE of the indicated constructs. Right panel: Illustrations of the indicated constructs.
[0041] Fig. 4 illustrates the alkoxyamine-functionalized peptide architecture. Numerous peptide structures for placement of the alkoxyamine on the peptide were evaluated, with the following two showing the best coupling: (1) C-terminal aminooxy-PEG2-amine (top panel) and (2) aminooxy acetic acid placed on the side chain of a C-terminal lysine residue (bottom panel). Illustrative peptide / linker sequences are NLVPMVATVGGG (SEQ ID NO:41) (top panel) and NLVPMVATVGGGK (SEQ ID NO:40) (bottom panel).
[0042] Fig. 5 illustrates three steps of oxime coupling. Step 1: An N-terminal serine on the beta2m is subjected to 10 min of oxidation at room temperature (RT) by addition of 5-50 equivalents of NalCL and quenched with 6 mM free serine. Steps 2 + 3: Overnight conjugation is performed at pH 5 with 5-50 eq. alkoxyamine substrate in the presence of aniline or p-PDA derivatives to form the resultant oxime-ligated product. Shorter incubation times can be used, such as 10 min. Numerous peptide structures for placement of the alkoxy amine on the peptide were evaluated, with C-terminal aminooxy -PEG2-amine and aminooxyacetic acid placed on the side chain of a C-terminal lysine residue showing the best coupling. The MHC scaffold is referred to as “Immuno-STAT” in the figure. The illustrative peptide sequence shown in Step 3 is the CMV pp65-derived NLVPMVATV (SEQ ID NO:39).8185193632.1
[0043] Fig. 6 illustrates the oxime-based conjugation of different antigenic peptides to MHC scaffolds based on HLA-A2. Aldehyde-alkoxyamine chemistry allowed for the near-quantitative coupling of a wide range of synthetic peptides to the MHC scaffolds. Samples were run under reducing conditions on a 12% Bis-Tris SDS-PAGE. Note the shift of the boxed bands relative to lanes 1 and 4, indicating conjugation of the antigenic peptide to the beta2m domain. Of particular note, aldehyde-alkoxyamine chemistry allowed for the attachment of post-translationally modified peptides (see #6 and #8), where “pS” indicates a phosphorylated serine residue. Sequences for the conjugated peptides (without linkers and functional groups) are as follows: #2 and #3: NLVPMVATV (SEQ ID NO:39); #5: VMIGSPKKV (SEQ ID NO:60); #6: VMIGpSPKKV (SEQ ID NO:61); #7: RVASPTSGV (SEQ ID NO:54); #8: RVApSPTSGV (SEQ ID NO:55); #9: YLQPRTFLL (SEQ ID NO:48).
[0044] Fig.7 illustrates the conjugation of difficult-to-express peptides to MHC scaffolds.Various HLA-A2-based protein complexes bearing peptides that have been predicted to bind MHC with high affinity have proven refractory to standard expression approaches. Aldehyde-alkoxyamine chemistry allowed for the near-quantitative coupling of the IV9 subdominant antigen from HIV (see #4), an epitope that is challenging to produce using standard recombinant expression technology. Sequences for the conjugated peptides (without linkers and functional groups) are as follows: #2: NLVPMVATV (SEQ ID NO:39); #4: ILKEPVHGV (SEQ ID NO:46); #6: SLYNTVATL (SEQ ID NO:44).
[0045] Fig.8 illustrates the conjugation of antigenic peptides to MHC scaffolds with a co-modulatory domain. Near-quantitative conjugation was observed with MHC scaffolds based on HLA-A2 comprising IL-2, IL-15 / Ralpha sushi, or CD28 agonist scFv co-modulatory domains, respectively. Conjugation was performed at a range of 10 min to overnight at RT. Sequence for the conjugated peptide (without linkers and functional groups): NLVPMVATV (SEQ ID NO:39).
[0046] Fig.9 illustrates the binding of a CMV-epitope bearing protein complex (without a co-modulatory domain) to Jurkat cells that express a cognate RA14 TCR. Protein complexes presenting a CMV pp65 peptide (based on HLA-A2) produced by recombinant means (left) and oxime-conjugated protein complexes (right) robustly bind to the cognate TCR on the surface of Jurkat cells transduced with a lentivirus to drive TCR expression (top). Protein complexes produced by recombinant means (left) and oxime-conjugated protein complexes9185193632.1(right) both showed minimal off-target binding when incubated with Jurkat cells transduced with a lentivirus driving expression of the non-cognate 1803 HIV-specific TCR.
[0047] Figs. 10A, 10B, and 10C illustrate that NaIO4-treated recombinant protein complexes bind to cognate receptors. The impact of NaIO4-mediated oxidation on the binding activity of several recombinantly produced protein complexes (with co-modulatory domains) was evaluated by subjecting recombinant HL A- A2 protein complexes bearing IL-2, IL-15 / Ralpha sushi, or CD28 agonist scFv (recombinantly expressed, not generated by oxime coupling) to the same procedure used to convert the N-terminal serine to an aldehyde functionality for subsequent conjugation. Protein complex binding was evaluated against HEK293 cells transfected with GFP and either IL-2R alpha, beta, gamma (for IL-2) (Fig.10A), IL-15R alpha, beta, gamma (for IL-15 / Ralpha sushi) (Fig. 10B). or CD28 (for CD28 agonist scFv) (Fig. 10C). Binding was quantified by FACS using an AF647-labeled anti-human antibody. Results show that NaIO4-mediated oxidation had no appreciable impact on the engagement of cognate receptors by the co-modulatory domains.
[0048] Fig. 11 shows that treatment with a protein complex without a co-modulatory domain stimulated in vitro expansion of CMV-specific CD8+T cells isolated from HLA-A*02:01 CMV-infected donors. PBMCs (Peripheral Blood Mononuclear Cells) from a representative CMV-positive donor with a CMV -targeting T cell precursor frequency of 0.97% of all CD8+T cells were treated with increasing concentrations of CMV- or HIV-conjugated protein complexes, cultured for 13 days in ImmunoCult-XF T Cell Expansion Media with added IL-2 (40 U / mL), and the fraction of CMV-specific CD8+T cells was determined by flow cytometric analysis. CMV -targeting recombinant protein complexes served as a positive control for expansion.
[0049] Fig. 12 illustrates that HLA-A2-based protein complexes comprising an IL-2 co-modulatory domain stimulated the in vitro expansion of CMV-specific CD8+T cells from HLA-A*02:01 CMV-positive donors. PBMCs from a representative CMV-infected donor (with a CMV-targeting T cell precursor frequency of 0.97% of all CD8+T cells) w ere treated with increasing concentrations of CMV- or HIV-conjugated IL-2 protein complexes comprising an IL-2 co-modulatory domain and cultured for 12 days in ImmunoCult-XF T Cell Expansion Media. The fraction of CMV-specific CD8+T cells was determined by flow cytometric analysis. CMV-targeting recombinant 1ST served as a positive control for expansion.10185193632.1
[0050] Fig. 13 illustrates a TEV cleavage strategy for the generation of N-terminal serine residues. An alternative production strategy for the generation of MHC scaffolds bearing an N-terminal serine residue utilized a covalently expressed peptide with a C-terminal TEV protease site. Overnight TEV cleavage allowed for the generation of a free N-terminal serine residue for subsequent oxidation and peptide coupling. The TEV protease recognition sequence with the highest catalytic efficiency is ENLYFQAS (SEQ ID NO:77). with cleavage atA.
[0051] Fig. 14 illustrates that TEV cleavage reveals a free N-terminal serine residue.MODLESS (no co-modulatory domain) and IL-2 bearing HLA-A2 -based protein complexes with internal TEV cleavage sites were treated with vary ing concentrations of TEV protease overnight at RT. Samples were run under reducing conditions on 4-12% Bis-Tris SDS-PAGE. Note the downward shift of the boxed bands, indicating successful cleavage of the N-terminally expressed peptide to generate an N-terminal serine.
[0052] Fig. 15 illustrates the oxime coupling of a cysteine-containing peptide to HLA-C*03:04-based MHC scaffold. Empty7HLA-C*03:04 MHC scaffolds were produced with an N-terminal serine residue for subsequent oxidation and coupling. Using aldehyde-alkoxy amine chemistry, a peptide of interest derived from IGRP was successfully coupled to the HLA-C*03:04 scaffold. Note that the shift of boxed bands indicates covalent attachment to the beta2m domain. Notably, this peptide contains a cysteine residue, which is not compatible with the most common coupling chemistries (e.g, thiol-mal eimide coupling).
[0053] Fig. 16 illustrates that CMV-specific CD8+T cells expanded by conjugated IL-2 and MODLESS 1ST expressed CD107a, IFNg, and TNFa. Expression of CD107a, IFNg, and TNFa in CMV-tetramer+ cells on day 14 following treatment. Previous gating is LIVE / DEAD Blue", CD8+, NLV tetramer+cells. Bars from left to right as in figure legend from top to bottom.
[0054] Fig. 17 illustrates that CMV-specific CD8+ T cells expanded by conjugated IL-2 and MODLESS 1ST exerted antigen-dependent elimination of target cells. Specific lysis of T2 cells loaded with CMV compared to HIV negative control 1 hour following 10:1 Effector: Target (E: T) co-culture with CD8-enriched effectors.
[0055] Fig. 18 illustrates nucleophilic nitrogen-containing peptide architectures. Each nucleophile can be installed on the side chain of an added lysine residue. The reactive nitrogen nucleophiles can also be tethered to the epsilon amino group of a lysine residue or tethered through linkers at the C-terminus composed of, but not limited to, peptidic linkers such as 11185193632.1(G4S)3 or GGG, or polyethylene glycol functionalities or others. The molecule on the upper right can also be referred to as a hydrazine.
[0056] Fig. 19 illustrates Alexa488 hydrazide conjugation to N-terminal serine beta2m.Beta2m bearing an N-terminal serine residue was successfully conjugated to an Alexa488 hydrazide substrate as shown by successful identification by STORM (Stochastic Optical Reconstruction Microscopy) (left) and Coomassie-stained SDS-PAGE (right). Circle indicates the site of conjugation.DETAILED DESCRIPTION
[0057] Provided herein are MHC -based biologies that are covalently coupled to peptide-based antigens.
[0058] Protein Complexes
[0059] Provided herein are TCR-binding complexes. In one aspect, the TCR-binding complex comprises an antigenic peptide (also referred to as ’‘epitope” herein) presented in the context of a major histocompatibility' complex (MHC) molecule.
[0060] Provided herein is an “MHC scaffold” that comprises one or more MHC molecules and that is suitable for conjugation with an epitope. In one aspect, provided is an MHC scaffold comprising:(a) an MHC complex comprising (i) a class I MHC heavy chain or a fragment, variant, or derivative thereof and (ii) a beta2m polypeptide or a fragment, variant, or derivative thereof:(b) optionally, a backbone polypeptide; and(c) optionally, one or more co-modulatory domains.
[0061] The MHC scaffold may be referred to herein as an “empty ” MHC scaffold ( / .<?., a scaffold suitable for being loaded with an epitope).
[0062] An MHC scaffold that is conjugated to an epitope is referred to herein as a “protein complex.” As such, in one aspect, provided is a protein complex comprising:(a) an MHC complex comprising (i) a class I MHC heavy chain or a fragment, variant, or derivative thereof and (ii) a beta2m polypeptide or a fragment, variant, or derivative thereof;(b) an epitope, wherein the epitope is covalently bound to the MHC complex;(c) optionally, a backbone polypeptide; and12185193632.1(d) optionally, one or more co-modulatory domains.
[0063] In one aspect, the epitope is covalently bound to the MHC complex via an oxime or hydrazone linkage.
[0064] The protein complex comprising the epitope may serve as a surrogate antigen-presenting cell and mimic the adaptive immune response. The protein complex may engage a TCR present on the surface of a T cell with the covalently bound epitope presented by the protein complex, resulting in epitope-specific cell targeting. In embodiments described herein, the protein complexes also possess at least one co-modulatory domain and / or cytokine or other signaling molecule that can engage a counterpart protein on the T cell. Both signals -epitope / MHC binding to a TCR and co-modulatory domain binding to its binding partner - can then drive both the desired T cell specificity and either inhibition, activation / proliferation, differentiation, or durability (depending on the co-modulatory domain(s) used). In one embodiment, the T cell is a CD8+T cell.
[0065] Previously, soluble MHC / peptide complexes have been developed for the stimulation of T cells, wherein the MHC / peptide complex comprised a peptide epitope, an MHC class I protein, and one or more co-modulators. In these MHC / peptide complexes, the peptide epitope was part of a single amino acid chain with the beta2m domain of the MHC class I protein. The entire multimeric protein (including the peptide) was expressed recombinantly in cells. See, e.g., International Patent Publication No. WO2015 / 195531, entitled “SYNTAC POLYPEPTIDES AND USES THEREOF,’7which is incorporated by reference in its entirety herein. However, multimeric proteins prepared by conventional recombinant expression technologies often exhibit multiple limitations: To start, to target a specific T cell (e.g, a T cell recognizing a neo-antigen on a patient’s tumor or a T cell recognizing a specific viral peptide presented on an infected cell or a T cell recognizing an autoimmune peptide on patient tissue), a person skilled in the art needs to generate an MHC complex presenting the specific peptide recognized by the T cell. However, in recombinantly expressed MHC / peptide complexes, peptide epitopes cannot be swapped out easily. Instead, in clinical settings, a person skilled in the art seeking to express an MHC / peptide complex with a different epitope needs to complete the costly and time-consuming process of generating a new master cell bank (e.g., in the development of new expression cell lines for clinical applications). Further, certain low-affinity peptides are not compatible with recombinant production technologies (i.e., fusion protein is not expressed or only at amounts insufficient for clinical or laboratory applications). Finally,13185193632.1antigenic peptides comprising post-translational modifications (e.g., phospho-peptides, which are widespread among tumor antigens) or non-natural amino acids cannot be produced using conventional methods.
[0066] Rather than expressing the epitope / MHC complex as part of a continuous chain, other methods have been contemplated, such as conjugation of the epitope to the MHC via a cystine using maleimide chemistry, for example, in International Patent Publication No. WO2021 / 195411A1. entitled “T cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof’ or using enzyme-mediated reactions such as SORTase A and subtiligase coupling. In cystine conjugation, the cystine residue in the protein to be conjugated is usually either naturally occurring at a desirable position or is introduced artificially at a desired position.
[0067] The compositions and methods disclosed herein involving oxime or hydrazone coupling provide significant benefits as compared to other mechanisms of conjugation, such as cystine conjugation. For example, before cystine coupling can occur, the MHC needs to be reduced (e.g, by incubating the protein in a reducing agent) to provide a cysteine site that can react with a functional group (e.g., maleimide) installed on the epitope. However, exposure of the MHC to reducing conditions might affect all cystines in the MHC and co-modulatory domains, many of which might be involved in disulfide bonds that are important for stability7and / or function. Even if the epitope only conjugates with the target cysteine, the MHC and co-modulatory domains might not be able to properly refold after being exposed to reducing conditions, again negatively affecting the structure and function of the entire complex. In contrast, the compositions and methods disclosed herein do not require a reduction before conjugation, preserving the structure and function of the MHC. Second, as mentioned above, in cystine coupling, the protein to be coupled is first reduced, which can lead to the exposure of cysteines that are usually involved in disulfide bonds. As such, the epitope might react with non-target cysteines in the MHC, which again can negatively7affect the structure and function of the MHC. In contrast, using the compositions and methods disclosed herein (and as shown in the Examples), off-target coupling that negatively affects function can be avoided. While during oxime coupling, the alkoxy amine epitope could theoretically conjugate to the aldehydes present in the carbohydrates of glycosylated MHC, this reaction is three orders of magnitude lower than the coupling reactions between the alkoxyamine epitope and the N-terminal aldehyde in the MHC. Additionally, oxime coupling will only target the N-terminal residue of 14185193632.1the MHC, not internal serine residues. Further, the compositions and methods disclosed herein can be used with cysteine containing epitopes, which are not compatible with cysteine coupling approaches due to the simultaneous inclusion of a thiol-reactive functionality such as maleimide in the peptide (i.e., the presence of both the free thiol of the cysteine and the maleimide functionality7in the peptide would lead to interpeptide crosslinking that competes with peptide coupling to the MHC scaffold). Finally, enzymatic coupling methods are often characterized by non-quantitative (70%) coupling yields associated with solubility issues (e., inability to drive the reaction to completion due to the solubility7of peptide-free Immuno-STATs, which is below the Km of the subtiligase and SORTase A coupling enzymes) as well as undesired side reactions (e.g., internal nucleophiles such as the epsilon-amino of lysine residues can result in internal crosslinking that competes with the exogenous nucleophile in the SORTase A-mediated reaction).
[0068] In contrast, the compositions and methods disclosed herein allow for the conjugation of peptides recalcitrant to standard recombinant expression technologies and enable coupling of peptides with post-translational modifications or unnatural amino acids that are not compatible with recombinant technologies.
[0069] MHC Molecules
[0070] Provided herein are protein complexes and MHC scaffolds comprising (i) a class I MHC heavy chain or a fragment, variant, or derivative thereof and (ii) a beta2m polypeptide or a fragment, variant, or derivative thereof.
[0071] MHC molecules are generally classified into two categories: class I and class IT MHCs.
[0072] An MHC class I molecule generally is an integral membrane protein comprising a glycoprotein heavy chain, also referred to herein as the alpha chain, which has three extracellular domains (e.g., alphal, alpha2 and alpha3). a transmembrane (TM) domain and a cytoplasmic (intracellular) domain. The heavy chain is noncovalently associated with a soluble subunit called P2-microglobulin (also referred to herein as beta2m or beta 2 microglobulin). Generally, class I molecules bind peptides of about 8-12 amino acids in length. Humans have between three and six different class I molecules, which can each bind many different types of peptides. In embodiments, the protein complexes and MHC scaffolds disclosed herein do not comprise a TM domain and / or a cytoplasmic (intracellular) domain. In embodiments, the protein complexes and MHC scaffolds disclosed herein comprise a TM domain and / or a cytoplasmic (intracellular) domain.15185193632.1
[0073] For reference, an MHC class II protein generally is a heterodimeric integral membrane protein comprising one alpha chain and one beta chain in noncovalent association. This alpha chain has two extracellular domains (alphal and alpha2), and a TM domain, and a cytoplasmic domain. The beta chain contains two extracellular domains (betal and beta2), and two intracellular domains (a TM domain and a CYT domain).
[0074] CD4+T cells usually bind to the MHC class II molecule. CD8+ T cells usually bind to the MHC class I molecule.
[0075] Naturally occurring MHC heavy chain molecules are encoded by a cluster of genes on human chromosome 6 or mouse chromosome 17. Said MHC molecules are referred to as H-2 in mice and HLA (Human Leucocyte Antigen) in humans.
[0076] In contrast to the class I MHC heavy chain, beta2m is a relatively non-polymorphic component of class I major histocompatibility complex proteins. Only seven beta2m alleles are known in the mouse, and only one has been identified in humans so far. Examples of naturally occurring beta2m are beta2m molecules encoded on human chromosome 15 and mouse chromosome 2.
[0077] The domain organization of MHC molecules forms the antigenic determinant binding site, or peptide binding groove. A ‘'peptide binding groove’’ refers to a portion of an MHC complex that forms a cavity in which a peptide (e.g., antigenic determinant) can bind. In naturally occurring MHC complexes, the conformation of a peptide binding groove is capable of being altered upon binding of a peptide to enable proper alignment of amino acid residues important for TCR binding to the peptide-MHC (pMHC) complex. The pMHC complex is also referred to herein as the MHC / peptide complex or MHC / epitope complex.
[0078] As used herein, class I “MHC polypeptides’’ or “MHC molecules” encompasses MHC class I alpha (heavy) chains. beta2m, individual subunits of such chains (e.g., alphal, alpha2, and / or alpha3 subunits of the MHC class I alpha chain) as well as fragments, variants, derivatives, or substantially engineered analogs. Usually, an MHC complex comprises more than one MHC polypeptide (e.g., an MHC class I alpha (heavy) chain and a beta2m). In some embodiments, the MHC complex comprises one or more MHC class I alpha heavy chains. In some embodiments, the MHC complex comprises one or more beta2m.
[0079] Provided herein is a protein complex or an MHC scaffold comprising an MHC complex comprising (i) a class I MHC heavy chain (or a fragment, variant, or derivative thereof), and (ii) a beta2m polypeptide (or a fragment, variant, or derivative thereof).16185193632.1
[0080] As used herein, a '’variant'’ or a “derivative” of a peptide or a polypeptide refers to a modified peptide or a polypeptide that comprises one or more alterations when compared to the parental peptide or polypeptide, including, but not limited to, amino acid additions, substitutions, insertions, deletions, or posttranslational modifications, wherein the variant or the derivative retains at least 10% of the biological activity7of the parental protein. In embodiments, the variant or derivative retains about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% of the biological activity of the parental protein. The variant or derivative may have a higher biological activity as compared to the parent peptide or polypeptide. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. With respect to an MHC molecule (such as an MHC heavy chain and / or a beta2m chain), the biological activity may refer to binding an epitope and / or displaying the epitope for recognition by T cells. In embodiments, the MHC molecule variant or MHC molecule derivative comprises modifications and / or amino substitutions that do not affect the functionality of the peptide binding groove. A variant may¬ be a substantially engineered analog of the parental protein. A variant may be computationally derived. An MHC vanant may be an engineered MHC construct comprising the peptide binding platform and the alphal and alpha2 helices that contact the TCR.
[0081] In some embodiments, the MHC class I heavy chain fragment, variant, or derivative thereof, or the beta2m fragment, variant, or derivative thereof, is a portion of the respective parental polypeptide that comprises a biologically active portion of the parental protein. In some embodiments, the MHC class I heavy chain variant or derivative thereof, or the beta2m variant or derivative thereof, comprises one or more mutations as compared to its respective parental counterpart. In some embodiments, the MHC class I heavy chain variant or derivative thereof, or the beta2m variant or derivative thereof, comprises 1, 2, 3, 4, 5. 6, 7, 8, 9, or 10 mutations as compared to its respective parental counterpart. In some embodiments, the MHC class I heavy7chain variant or derivative thereof, or the beta2m variant or derivative thereof, comprises one or more mutations as compared to its respective parental counterpart. In some embodiments, the MHC class I heavy chain variant or derivative thereof, or the beta2m variant or derivative thereof, comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative mutations as compared to its respective parental counterpart.
[0082] The terms “amino acid substitution” and “amino acid mutation” are used interchangeably herein. As used herein, the terms “conservative amino acid substitutions” and 17185193632.1“conservative modifications'’ refer to amino acid modifications that do not significantly affect or alter the function and / or activity of the presently disclosed proteins comprising the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the proteins of this disclosure by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.
[0083] Amino acids can be classified into groups according to their physicochemical properties, such as charge and polarity. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid within the same group. For example, amino acids can be classified by charge: positively-charged amino acids include lysine, arginine, and histidine; negatively-charged amino acids include aspartic acid and glutamic acid; neutral charge amino acids include alanine, asparagine, cysteine, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. In addition, amino acids can be classified by polarity: polar amino acids include arginine (basic polar), asparagine, aspartic acid (acidic polar), glutamic acid (acidic polar), glutamine, histidine (basic polar), lysine (basic polar), serine, threonine, and tyrosine; nonpolar amino acids include alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine.
[0084] Human and other mammalian MHC molecules are well known in the art and may be used in the compositions and methods disclosed herein.
[0085] MHC molecules useful in the protein complexes and MHC scaffolds described herein include naturally occurring full-length MHC molecules, as well as individual chains of MHC molecules (e.g., MHC class I alpha (heavy) chain, beta2m, individual subunits of such chains of MHCs (e.g., alphal, alpha2, and / or alpha3 subunits of MHC class I alpha chain), as well as fragments, variants, derivatives, or substantially engineered analogs, wherein such fragments, variants, derivatives, and engineered analogs retain the ability to display an antigenic determinant for recognition by an antigen-specific TCR.
[0086] Also useful in the protein complexes and MHC scaffolds described herein are engineered analogs of MHC molecules. For example, useful for the compositions and methods disclosed herein are engineered MHCs that preserve the peptide binding groove but comprise modifications that enhance stability' and / or support additional functionality (e.g., additional receptor binding functions or enzy matic functions).18185193632.1
[0087] The MHC complexes described herein may include fragments of MHC chains that are sufficient to form a peptide binding groove. For example, a peptide binding groove of a class I protein can comprise portions of the alphal and alpha2 domains of the heavy chain, or surrogate structures, capable of forming two beta-pleated sheets and two alpha helices. Inclusion of a portion of the beta2m chain, or a surrogate structure, can stabilize the complex.
[0088] The MHC complexes useful in the protein complexes described herein may be from, but are not limited to, any mammalian or avian species, for example, primates (e.g, humans), rodents (e.g, mouse, rat, rabbit, etc.), equines, bovines, canines, felines, pigs, non-human primates, canines, and the like. Not all MHC molecules that make up an MHC complex have to be derived from the same organism.
[0089] MHC molecules include, but are not limited to, MHC molecules with HLA specificities such as A (e.g., A1-A74), B (e.g., B1-B77), C (e.g., Cl-Cl 1), D (e.g., D1-D26), E, F, and G. More preferably, HLA specificities include Al, A2, A3, All, A23, A24, A28, A30, A33, B7, B8, B35, B44, B53, B60, and B62.
[0090] In one embodiment, the class I MHC molecules are human class I MHC molecules selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-K, or HLA-L. Class I human MHC polypeptides may be drawn from classical HLA alleles (HLA-A, B, and C), or non-classical HLA alleles (e.g., HLA-E, F, and G).
[0091] In one embodiment, the class I MHC molecules are human class I MHC molecules selected from the group consisting of HLA-A. HLA-B, and HLA-C.
[0092] In some embodiments, the class I MHC molecules are derived from an HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*ll:0I, HLA-A*23:01, HLA-A*24:02, HLA-A*24:07, HLA-A*33:03, HLA-A*34:01, HLA-B*07:02, HLA-B*08:01, HLA-B*15:02, HLA-B*35:01. HLA-B*38:02, HLA-B*40:01, HLA-B*44:02, HLA-B*44:03, HLA-B*46:01, HLA-B*53:0L HLA-B*58:01, HLA-C*01:02, HLA-C*03:03, HLA-C*03:04, HLA-C*04:0I, HLA-C*06:02, HLA-C*07:0I, HLA-C*07:02, HLA-C*08:01, or HLA-C*I5:02, an HLA-E polypeptide, an HLA-F polypeptide, or an HLA-G polypeptide.
[0093] In some embodiments, the class I MHC molecules are murine class I MHC molecules selected from the group consisting of H-2K, H-2D, H-2L, H2-IA, H2-IB, H2-IJ, H2-IE, and H2-IC.19185193632.1
[0094] In some embodiments, the MHC heavy chain comprises a simian class I MHC polypeptide derived from classical (MHC class la) genes A, B, and C, or “non-classical” (MHC class lb) genes E, F, and G.
[0095] In some embodiments, the MHC heavy chain comprises a canine class I MHC polypeptide derived from DLA-I.
[0096] In some embodiments, the HLA-A molecules, or portions thereof, that may be incorporated into a protein complex or an MHC scaffold disclosed herein include, but are not limited to, the following alleles: A*0101, A*0201, A*0301, A*1101, A*2301, A*2402, A*2407, A*3303, and A*3401. Any of those alleles may comprise a substitution, for example, at one or more of positions 84, 139, and 236, for example, selected from: a tyrosine to alanine at position 84 (Y84A); a tyrosine to cysteine at position 84 (Y84C); an alanine to cysteine at position 139 (A139C); and an alanine to cysteine substitution at position 236 (A236C).
[0097] In some embodiments, the HLA-B molecules, or portions thereof, that may be incorporated into a protein complex or an MHC scaffold disclosed herein include, but are not limited to, the following alleles: B*0702, B*0801. B*1502, B*3802, B*4001, B*460I, and B*5301. Any of those alleles may comprise a substitution at one or more of positions 84, 139, and 236, for example, selected from: a tyrosine to alanine at position 84 (Y84A); a tyrosine to cysteine at position 84 (Y84C); an alanine to cysteine at position 139 (A139C); and an alanine to cysteine at position 236 (A236C).
[0098] In some embodiments, the HLA-C molecules, or portions thereof, that may be incorporated into a protein complex or an MHC scaffold disclosed herein include, but are not limited to, the following alleles: C*0102, C*0303, C*0304, C*0401, C*0602, C*070I, C*0702, C*0801, and C* 1502. Any of those alleles may comprise a substitution at one or more of positions 84, 139. and / or 236, for example, selected from: a tyrosine to alanine at position 84 (Y84A); a tyrosine to cysteine at position 84 (Y84C); an alanine to cysteine at position 139 (A139C); and an alanine to cysteine at position 236 (A236C).
[0099] In some embodiments, non-classical HLA molecules, or portions thereof, are incorporated into an MHC complex disclosed herein, including, but not limited to, those of the HLA-E, F, and / or G alleles. Sequences for those alleles, (and the HLA-A, B, and C alleles) may be found on the world wide web at, for example, hla.alleles.org / nomenclature / index.html, the European Bioinformatics Institute (www.ebi.ac.uk), which is part of the European20185193632.1Molecular Biology Laboratory' (EMBL), and the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).
[0100] Some suitable HLA-E alleles include, but are not limited to, HLA-E*0101 (HLA-E*01:01:01:01), HLA-E*01:03 (HLA-E*01:03:01:01), HLA-E*01:04, HLA-E*01:05, HLA-E*01: 06, HLA-E*01: 07, HLA-E*01: 09, and HLA-E*01:10.
[0101] Some suitable HLA-F alleles include, but are not limited to, HLA-F*0101 (HLA-F*01:01:01:01), HLA-F*01:02, HLA-F*01:03 (HLA-F*01:03:01:01), HLA-F*01:04, HLA-F*01:05, and HLA-F*01:06.
[0102] Some suitable HLA-G alleles include, but are not limited to, HLA-G*0101 (HLA-G* 01: 01: 01: 01 ), HLA-G*01: 02, HLA-G* 01:03 (HLA-G*01:03:01:01), HL A-G*01: 04 (HL A-G*01:04:01:01), HLA-G*01:06, HLA-G*01:07, HLA-G*01:08, HLA-G*01:09, HLA-G*01:10, HLA-G*01:l l, HLA-G*01:12, HLA-G*01:14, HLA-G*01:15, HLA-G*01:16, HL A-G*01: 17, HLA-G* 01:18, HL A-G* 01: 19, HLA-G* 01: 20, and HL A-G*01: 22.
[0103] Any of the above-mentioned HLA-E, F, and / or G alleles may comprise a substitution at one or more of positions 84, 139. and / or 236. In an embodiment, the substitutions may be selected from: a position 84 tyrosine to alanine (Y84A) or cysteine (Y84C), or in the case of HLA-F, a R84A or R84C substitution; a position 139 alanine to cysteine (A139C), or in the case of HLA-F, a V139C substitution; and an alanine to cysteine at position 236 (A236C).
[0104] Substitution of position 84 of the MHC heavy chain, particularly when it is a tyrosine residue, with a small amino acid such as alanine (Y84A) tends to open one end of the MHC binding pocket, allowing a linker (e.g, attached to an epitope peptide) to “thread” through the end of the pocket, and accordingly, permits a greater variation in the size of the epitope (e.g, longer peptides bearing epitope sequences) that can fit into the MHC pocket and be presented by the protein complex.
[0105] In an embodiment, the HLA-A heavy chain polypeptide of an MHC complex disclosed herein comprises Y84C and A139C substitutions. When amino acids 84 and 139 of the class I MHC heavy chain are both cysteines, they may form an intrachain disulfide bond which can stabilize the MHC complex and facilitate translation and secretion of the protein complexes by eukaryotic cells, even when not loaded with an epitope peptide.
[0106] When amino acid 236 of the class I MHC heavy chain is a cysteine, it can form an interchain disulfide bond with a cysteine at amino acid 12 of a variant beta2m polypeptide that comprises an R12C substitution at that position.21185193632.1
[0107] In some embodiments, the MHC class I molecule comprises a mutation in a beta2m polypeptide and in the heavy chain sequence so as to affect a disulfide bond between the beta2m and the heavy chain. In some cases, the heavy chain is an HLA, and wherein the disulfide bond links one of the following pairs of residues: beta2m residue 12, HLA residue 236; beta2m residue 12, HLA residue 237; beta2m residue 8, HLA residue 234; beta2m residue 10, HLA residue 235; beta2m residue 24, HLA residue 236; beta2m residue 28, HLA residue 232; beta2m residue 98, HLA residue 192; beta2m residue 99, HLA residue 234; beta2m residue 3, HLA residue 120; beta2m residue 31, HLA residue 96; beta2m residue 53, HLA residue 35; beta2m residue 60, HLA residue 96; beta2m residue 60, HLA residue 122; beta2m residue 63, HLA residue 27; beta2m residue Arg3, HLA residue Glyl20; beta2m residue His31, HLA residue Gln96; beta2m residue Asp53. HLA residue Arg35; beta2m residue Trp60, HLA residue Gln96; beta2m residue Trp60, HLA residue Aspl22; beta2m residue Tyr63, HLA residue Tyr27; beta2m residue Lys6, HLA residue Glu232; beta2m residue Gln8, HLA residue Arg234; beta2m residue TyrlO, HLA residue Pro235; beta2m residue Serll, HLA residue Gln242; beta2m residue Asn24, HLA residue Ala236; beta2m residue Ser28, HLA residue Glu232; beta2m residue Asp98, HLA residue His 192; and beta2m residue Met99, HLA residue Arg234; first linker position Gly2, Heavy Chain (HLA) position Tyr84; Light Chain (beta2m) position Argl2, HLA Ala236; and / or beta2m residue Argl2, HLA residue Gly237. See, e.g., Int. Pat. Appl. Pub. WO2015 / 195531, incorporated herein by reference in its entirety.
[0108] In some embodiments, the MHC class I alpha heavy chain is fully human. In some embodiments, the MHC class I alpha heavy chain is humanized. Humanized MHC class I alpha heavy chains are known in the art and are described, e.g., in U. S. Pat. Pub. Nos. 2013 / 0111617, 2013 / 0185819, and 2014 / 0245467, which are incorporated herein by reference in their entireties.
[0109] In some embodiments, the MHC complex includes all the domains of an MHC class I heavy chain. In some embodiments, the MHC class I heavy chain does not include a signal peptide, a transmembrane domain, and / or an intracellular domain (cytoplasmic tail) associated with a native MHC class I heavy chain. In some embodiments, the MHC Class I heavy chain present in an MHC complex disclosed herein includes only the alphal, alpha2, and alpha3 domains of an MHC Class I heavy chain. In some embodiments, the MHC Class I heavy chain has a length of from about 270 amino acids (aa) to about 290 aa. In some cases, the MHC class I heavy chain has a length of 270 aa, 271 aa, 272 aa, 273 aa. 274 aa, 275 aa, 276 aa, 277 aa,22185193632.1278 aa, 279 aa, 280 aa, 281 aa, 282 aa, 283 aa, 284 aa, 285 aa, 286 aa, 287 aa, 288 aa, 289 aa, or 290 aa.
[0110] In some embodiments, the beta2m is fully human. In some embodiments, the beta2m is humanized. Humanized beta2m polypeptides are known in the art and are described, e.g., in U. S. Pat. Pub. Nos. 2013 / 0111617 and 2013 / 0185819, which are incorporated herein by reference in their entireties.
[0111] In some embodiments, the beta2m sequence comprises a full-length beta2m sequence. In some embodiments, the beta2m sequence lacks the leader peptide sequence. In some embodiments, the beta2m sequence can comprise about 99 amino acids, and can be a mouse beta2m sequence (e.g, GenBank X01838). In some embodiments, the beta2m sequence can comprise about 99 amino acids, and can be a human beta2m sequence (e.g., GenBank AF072097.1).
[0112] In some embodiments, the MHC complex comprises an MHC class I heavy chain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%, at least 95%, at least 96%, at least 97%, at least 98%. or at least 99% identical to any one of SEQ ID NOs: 16-18. In some embodiments, the MHC complex comprises any one of SEQ ID NOs: 16-18. In some embodiments, the MHC complex comprises an MHC class I heavy chain that has at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions as compared to any one of SEQ ID NOs: 16-18.
[0113] In some embodiments, the MHC complex comprises a beta2m molecule comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:21 or SEQ ID NO:22. In some embodiments, the MHC complex comprises a beta2m molecule comprising SEQ ID NO:21 or SEQ ID NO:22. In some embodiments, the MHC complex comprises a beta2m molecule that has at 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions as compared to SEQ ID NO:21 or SEQ ID NO:22.
[0114] Backbone Polypeptides
[0115] Provided herein are MHC scaffolds and protein complexes comprising a backbone polypeptide. Suitable backbone polypeptides can be in vivo half-life extending polypeptides. Thus, in embodiments, an inclusion of a backbone polypeptide in the protein complex or the MHC scaffold increases the in vivo half-life (e.g, the serum half-life) of the protein complex or the MHC scaffold, compared to a control protein complex or the MHC scaffold lacking the 23185193632.1backbone polypeptide. In some embodiments, a backbone polypeptide increases the in vivo half-life of the protein complex or the MHC scaffold, compared to a control protein complex or the MHC scaffold lacking the backbone polypeptide, by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 50%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 25-fold, at least about 50-fold, at least about 100-fold, or more than 100-fold.
[0116] In one embodiment, the MHC complex is conjugated to an Fc backbone. The Fc polypeptide can be, for example, derived from an IgA, IgD, IgE, IgG, or IgM. In some embodiments, the Fc region may contain or be derived from a human polypeptide sequence, a humanized polypeptide sequence, a Fc region polypeptide of a synthetic heavy chain constant region, or a consensus heavy chain constant region. In embodiments, the Fc polypeptide can be derived from a human IgGl Fc, a human IgG2 Fc, a human IgG3 Fc, a human IgG4 Fc, a human IgA Fc, a human IgD Fc, a human IgE Fc, a human IgM Fc, etc.
[0117] In some embodiments, the Fc region has a N297 mutation (N297 in IgGl or equivalent position in another immunoglobulin), which reduces glycosylation and reduces binding to Fc receptors. This mutation can be made by substituting the N297 amino acid with alanine (N297A), glycine (N297G), or glutamine (N297Q). In some embodiments, the Fc region has an L234A substitution and an L235 A substitution (L234 / L235 in IgGl or equivalent position in another immunoglobulin), an antibody mutation that reduces binding to FcgammaRs and Clq.
[0118] The Fc region may comprise Fc CH2 and CH3 domains or portions thereof.
[0119] In some embodiments, the protein complex comprises a backbone polypeptide comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%. at least 94%, at least 95%, at least 96%, at least 97%, at least 98%. or at least 99% identical to any of SEQ ID NO: 19 or 20. In some embodiments, the protein complex comprises a backbone polypeptide comprising SEQ ID NO: 19 or 20.
[0120] In some embodiments, an immunoglobulin sequence may undergo proteolysis such that some amino acids are lost from the carboxyl terminal end. In particular, a terminal lysine may be removed / lost during cellular processing of the protein complexes or MHC scaffolds, and accordingly, those amino acids may not be present on some or all of the protein complexes or MHC scaffolds as expressed.24185193632.1
[0121] In one embodiment, the backbone polypeptide is antibody-based. In one embodiment, the backbone polypeptide is a non-antibody-based backbone. Non-antibody-based backbones include, e.g, albumin; an XTEN (extended recombinant) polypeptide; transferrin; a Fc receptor polypeptide; an elastin-like polypeptide (see, e.g., Hassouneh et al, Fusions of elastin-like polypeptides to pharmaceutical proteins, Methods Enzymol.2012;502:215-37 (e.g., a polypeptide comprising a pentapeptide repeat unit of (Val-Pro-Gly-X-Gly), where X is any amino acid other than proline)); an albumin-binding polypeptide; a silk-like polypeptide (see, e.g., Valluzzi et al, Silk: molecular organization and control of assembly, Philos Trans R Soc Lond B Biol Sci. 2002 Feb 28;357(1418): 165-7); a silk-elastin-like polypeptide (SELP; see, e.g., Megeed et al., Genetically engineered silk-elastinlike protein polymers for controlled drug delivery. Adv Drug Deliv Rev. 2002 Oct 18;54(8): 1075-91), and the like. Suitable XTEN polypeptides include, e.g., those disclosed in WO 2009 / 023270, WO 2010 / 091122, WO 2007 / 103515, US 2010 / 0189682, and US 2009 / 0092582; see also Schellenberger et al., A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009 Dec;27(12): 1186-90. Suitable albumin polypeptides include, e.g., human serum albumin.
[0122] Co-Modulatory Domains
[0123] As discussed herein, during an immune response, multiple signals provided by antigen-presenting cells (APCs) are utilized to activate antigen-specific naive T cells. The first signal is an antigen-specific signal, resulting from the TCR’s recognition of its cognate peptide: MHC complex. The second signal is a co-stimulatory signal conveyed through one of several receptors on the T cell’s surface. For example, B7 located on the APC’s surface, stimulates CD28, on the T cell’s surface. Additional growth and differentiation signals are provided by cytokines, such as IL-2 and IL-15.
[0124] As such, the protein complexes or MHC scaffolds disclosed herein may comprise one or more co-modulatory domains. A “co-modulatory domain” may also be referred to as an “immunomodulatory domain” and can provide, for example, a stimulatory, an inhibitory, or a differentiation signal to a cell. For example, a co-modulatory domain might bind to a cognate polypeptide on a cell (e.g, a T cell), thereby providing a signal which mediates a cellular response (e.g., a T cell response) including, but not limited to, proliferation, activation, differentiation, durability, and the like.25185193632.1
[0125] Co-modulatory domains are known in the art. In some embodiments, the co-modulatory domain binds to a molecule expressed on a cell as shown in Table 1 (or a variant or a derivative thereof). In some embodiments, the co-modulatory domain is a co-modulatory domain shown in Table 1, or a variant or a derivative thereof.
[0126] Co-modulatory domains include, but are not limited to, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, Fas ligand (FasL), inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), transforming growth factor beta (TGF-b), CD30L, CD40, CD70, CD83, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, HVEM, an agonist or antibody that binds the Toll ligand receptor, and a ligand that specifically binds withB7-H3.
[0127] Co-modulatory domains also include, but are not limited to. agents that bind (e.g., an antibody (or an antigen binding portion thereof, such as a Fab)) to a cognate polypeptide present on a cell (such as a T cell), including, but not limited to, CD27, CD28, 4- IBB, 0X40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, LIGHT, NKG2C, B7-H3. and a ligand that specifically binds to CD83.
[0128] Co-modulatory domains include polypeptides that act as a co-modulatory domain.Table 1. Examples of co-modulatory interactions.26185193632.1
[0129] In one embodiment, the co-modulatory domain comprises IL-2, which may be affinity attenuated. The protein complex may comprise more than one IL-2 copy.
[0130] In one embodiment, the co-modulatory domain comprises a CD38 agonist.
[0131] In one embodiment, the co-modulatory domain comprises IL-15Ra sushi and / or IL-15. In one embodiment, the co-modulatory domain comprises an IL-15-sushi / IL-15 fusion protein.
[0132] In some embodiments, the protein complex comprises one or more co-modulatory domains comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs:23-27. In some embodiments, the co-modulatory domain comprises one or more of SEQ ID NOs:23-27. In some embodiments, the co-modulatory domain comprises a sequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions as compared to any one of SEQ ID NOs:23-27. The co-modulatory domain may be expressed with or without a signal peptide.
[0133] In some embodiments, the protein complex or the MHC scaffold disclosed herein comprises a co-modulatory domain that has a binding affinity (i.e., equilibrium dissociation constant or Kd) for its binding partner on the surface of a cell that is from 1 pM to 100 mM. For example, in some cases, a co-modulatory domain that has a binding affinity for its binding partner that is from about 100 nM to about 150 nM, from about 100 nM to about 500 nM, from about 150 nM to about 200 nM, from about 200 nM to about 250 nM, from about 250 nM to about 300 nM. from about 300 nM to about 350 nM, from about 350 nM to about 400 nM, from about 400 nM to about 500 nM, from about 500 nM to about 600 nM, from about 500 nM to about 1 mM, from about 600 nM to about 700 nM, from about 700 nM to about 800 nM, from about 800 nM to about 900 nM, from about 900 nM to about 1 pM, from about 1 pM to about 5 pM, from about 1 pM to about 25 pM from about 5 pM to about 10 pM, from about 10 pM to about 15 pM, from about 15 pM to about 20 pM, from about 20 pM to about 25 pM, from about 25 pM to about 50 pM, from about 25 pM to about 100 pM, from about 50 pM to about 75 pM, or from about 75 pM to about 100 pM.27185193632.1
[0134] Epitopes
[0135] Naturally occurring MHC class I molecules bind peptides derived from proteolytically degraded proteins, especially endogenously synthesized proteins and exogenous proteins generated by cross-presentation. Small peptides obtained accordingly are transported into the endoplasmic reticulum, where they associate with nascent MHC class I molecules before being routed through the Golgi apparatus and displayed on the cell surface for recognition by cytotoxic T lymphocytes.
[0136] As used herein, the peptide displayed on an MHC complex may also be referred to as an “epitope” or an “antigenic determinant”. The terms “peptide,” “antigenic determinant” and “epitope” as used herein encompass not only those presented naturally by antigen-presenting cells (APCs) but may be any desired peptide or peptide-like variant so long as it is presented on an MHC complex, and may or may not be recognized by an immune cell, e.g, when presented appropriately to the cells of an immune system.
[0137] The epitope is usually between about 5 amino acids to about 40 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 6 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 7 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 8 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 9 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 10 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 11 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 12 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 13 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 14 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 15 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 16 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 17 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 18 amino acids in length. In some embodiments, the epitope (by itself or in combination w ith one or more linkers) is 19 amino acids in length. In some embodiments, the epitope (by itself or in 28185193632.1combination with one or more linkers) is 20 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 21 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 22 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 23 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 24 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 25 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 26 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 27 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 28 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 29 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 30 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 31 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 32 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 33 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 34 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 35 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 36 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 37 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 38 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 39 amino acids in length. In some embodiments, the epitope (by itself or in combination with one or more linkers) is 40 amino acids in length.
[0138] In some embodiments, the antigenic determinant amino acid sequence can be that of a peptide which can be presented by an MHC class I molecule. In certain embodiments, the sequence can comprise from about 8 to about 15 contiguous amino acids. In certain embodiments, a peptide sequence can be that of a protein fragment, wherein the protein is derived from, e.g, a portion of, an infectious agent or a cellular protein, such as, for example,29185193632.1a protein expressed by a cancer cell, and wherein the peptide can be bound to the MHC class I heavy chain.
[0139] In one embodiment, the epitope is a post-translationally modified (PTM) peptide. PTMs are well-known neo-antigens in infectious diseases (e.g, HIV), autoimmune diseases, and oncology' indications, and thus afford novel therapeutic strategies.
[0140] In one embodiment, the epitope is derived from a bacterial pathogen. Non-limiting examples of bacterial proteins which may be a source of bacterial peptides, e.g, antigenic determinants, that can be used in the protein complexes described herein include lipopolysaccharides isolated from gram-negative bacterial cell walls and staphylococcusspecific, streptococcus-specific, pneumococcus-specific (e.g., PspA; see PCT Publication No. WO 1992 / 14488, which is incorporated herein by reference in its entirety), Neisseria gonorrhea-specific, Borrelia-specific (e.g, OspA, OspB, OspC of Borrelia associated with Lyme disease such as Borrelia burgdorferi, Borrelia afzelii, and Borrelia garinii (see, e.g., U. S. Pat. No. 5,523,089; PCT Publication Nos. WO 90 / 04411, WO 91 / 09870, WO 93 / 04175, WO 96 / 06165, W093 / 08306; PCT / US92 / 08697; Jonsson et al., Heterogeneity of outer membrane proteins in Borrelia burgdorferi: comparison of osp operons of three isolates of different geographic origins. Infect Immun. 1992 May;60(5): 1845-53; Johnson et al., Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Vaccine. 1995 Aug;13(12): 1086-94; Edelman. The Sixth International Conference on Lyme Borreliosis: progress on the development of Lyme disease vaccines. 19-22 June 1994, Bologna, Italy. Vaccine. 1995 Jan;13(l): 133-5, all of which are incorporated herein by reference in their entireties), and pseudomonas-specific proteins or peptides. Additional non-limiting examples of bacterial antigens include, e, antigens from Neisseria gonorrhea, Mycobacterium tuberculosis, Haemophilus vaginalis, Group B Streptococcus sp., Mycoplasma hominis, Hemophilus ducreyi, Granuloma inguinale, Lymphopathia venereum, Treponema pallidum, Brucella abortus, Brucella melitensis, Brucella suis, Brucella canis, Campylobacter fetus, Campylobacter fetus intestinalis, Leptospira pomona. Listeria monocytogenes, Brucella ovis, Chlamydia psittaci, Escherichia coh. Actinobacillus equuli. Salmonella abortus ovis. Salmonella abortus equi, Pseudomonas aeruginosa, Corynebacterium equi, Corynebacterium pyogenes, and Actinobacillus seminis.30185193632.1
[0141] In one embodiment, the epitope is derived from a viral pathogen. In one embodiment, the epitope is derived from a viral protein, including, but not limited to, LCMV gp33, CMV pp65, HIV gag, HIV reverse transcriptase, SARS-CoV-2 spike protein, and EBV BMLF1. In some embodiments, the epitope is derived from influenza virus (e.g., surface glycoproteins hemagglutinin (HA) and neuraminidase (NA)); immunodeficiency virus (e.g., a human immunodeficiency virus antigen (HIV) such as gp120, gp160, p18 antigen Gag p!7 / p24, Tat, Pol, Nef, and Env); herpesvirus (e.g., a glycoprotein from herpes simplex virus (HSV), Marek's Disease Virus, cytomegalovirus (CMV), or Epstein-Barr virus); hepatitis virus (e.g, Hepatitis B surface antigen (HBsAg)); papilloma vims; rous-associated vims (e.g., RAV-1 env); infectious bronchitis virus (e.g., matrix and / or preplomer); flavivirus (e.g., a Japanese encephalitis virus (JEV) antigen, a Yellow Fever antigen, or a Dengue virus antigen); Morbillivirus (e.g, a canine distemper virus antigen, a measles antigen, or rinderpest antigen such as HA or F); rabies (e.g., rabies glycoprotein G); parvovirus (e.g., a canine parvovirus antigen); poxvirus (e.g., an ectromelia antigen, a canary poxvirus antigen, or a fowl poxvirus antigen); chicken pox virus (varicella zoster antigen); infectious bursal disease virus (e.g., VP2, VP3, or VP4); Hantaan vims, and mumps vims. In some embodiments, the epitope is derived from CMV, HIV, hepatitis vims, or SARS-CoV-2 vims.
[0142] In one embodiment, the epitope is derived from a pathogenic protozoon. In one embodiment, the epitope is derived from Plasmodium, such as P. falciparum, P. vivax, P. ovale or P. malariae.
[0143] In one embodiment, the epitope is derived from a malaria-specific protein, including, but not limited to, circumsporozoite (CS) protein, Thrombospondin Related Adhesion protein (TRAP), also called Sporozoite Surface Protein 2 (SSP2), LSA I, hsp70, SALSA, STARP, Hep 17. MSA, RAP-1, RAP-2.
[0144] In one embodiment, the epitope is derived from a multicellular organism including, but not limited to, Schistosoma mansoni, Nippostrongylus brasiliensis, or H. polygyrus.
[0145] In one embodiment, the epitope is derived from a fungal pathogen. Non-limiting examples of fungal proteins from which antigenic determinants may be isolated include those isolated from Candida (e.g., MP65 from Candida albicans), trichophyton, and ptyrosporum.
[0146] In some embodiments, the epitope is a helminth parasite peptide or an ectoparasite peptide.31185193632.1
[0147] In some embodiments, the epitope is derived from islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), insulin receptor 2 (IRS2), or tensin-3.
[0148] In one embodiment, the epitope is a cancer antigen, also referred to herein as a tumor antigen. Non-limiting examples of tumor-associated proteins from which antigenic determinants may be isolated include, e.g., adipophilin, AIM-2, ALDH1A1, alpha-actinin-4, alpha-fetoprotein (“AFP”), ARTCI. B-RAF, BAGE-1, BCLX (L). BCR-ABL fusion protein b3a2, beta-catenin, BING-4, CA-125, CALCA, carcinoembryonic antigen (“CEA”), CASP-5, CASP-8, CD274, CD45, Cdc27, CDK12, CDK4, CDKN2A, CEA, CLPP, COA-1, CPSF, CSNK1A1, CTAG1, CTAG2, cyclin DI, Cyclin-Al, dek-can fusion protein, DKK1, EFTUD2, Elongation factor 2, ENAH (hMena), Ep-CAM, EpCAM, EphA3, epithelial tumor antigen (“ETA”). ETV6-AML1 fusion protein, EZH2, FGF5, FLT3-ITD, FN1. G250 / MN / CAIX, GAGE-1,2,8, GAGE-3,4,5,6,7, GAS7, glypican-3, GnTV, gp!00 / Pmell7, GPNMB, HAUS3, Hepsin, HER-2 / neu, HERV-K-MEL, HLA-A11, HLA-A2, HLA-DOB, hsp70-2, IDO1, IGF2B3, IL13Ralpha2, Intestinal carboxyl esterase, K-ras, Kallikrein 4, KIF20A, KK-LC-1, KKLC1, KM-HN-1. KMHN1 also known as CCDC110. LAGE-1, LDLR-fucosyltransferaseAS fusion protein, Lengsin, M-CSF, MAGE-A1, MAGE-A10, MAGE-A12, MAGE-A2, MAGE- A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-CI, MAGE-C2, malic enzyme, mammaglobin-A, MART2, MATN, MC1R, MCSP, mdm-2, MEI, Melan-A / MART-1, Meloe, Midkine, MMP-2, MMP-7, MUC1, MUC5AC, mucin, MUM-1, MUM-2, MUM-3, Myosin, Myosin class I. N-ras. NA88-A. neo-PAP, NFYC, NY-BR-1, NY-ESO-l / LAGE-2, OA1, OGT, OS-9, P polypeptide, p53, PAP, PAX5, PBF, pml-RARalpha fusion protein, polymorphic epithelial mucin (“PEM”), PPP1R3B, PRAME, PRDX5, PSA, PSMA, PTPRK, RAB38 / NY-MEL-1, RAGE-1, RBAF600, RGS5, RhoC, RNF43, RU2AS, SAGE, secemin 1, SIRT2. SNRPD1, SOX10. Spl7, SPA17, SSX-2. SSX-4. STEAP1, survivin, SYT-SSX1 or -SSX2 fusion protein, TAG-1, TAG-2, Telomerase, TGF-betaRII, TPBG, TRAG-3, Triosephosphate isomerase, TRP-l / gp75, TRP-2, TRP2-INT2, tyrosinase, tyrosinase (“TYR”), VEGF, WT1, XAGE-lb / GAGED2a, Kras, NY-ESO1, MAGE-A3, HPV E2, HPV E6, HPV E7, WT-1 antigen (in lymphoma and other solid tumors), ErbB receptors, Melan A [MARTI], gp 100, tyrosinase, TRP-l / gp 75, and TRP-2 (in melanoma); MAGE-1 and MAGE-3 (in bladder, head and neck, and non-small cell carcinoma); HPV E6 and E7 proteins (in cervical cancer); Mucin [MUC-1] (in breast, pancreas, colon, and prostate cancers); prostate-specific antigen [PSA] (in prostate cancer); carcinoembryonic antigen [CEA] (in colon, breast, and 32185193632.1gastrointestinal cancers), and such shared tumor-specific antigens as MAGE-2, MAGE-4, MAGE-6, MAGE-10, MAGE-12, BAGE-1, CAGE-1,2,8, CAGE-3 to 7. LAGE-1, NY-ESO-1 / LAGE-2, NA-88, GnTV, TRP2-INT2. In some embodiments, the protein is a neo-antigen. In some embodiments, the protein is a tumor-specific antigen.
[0149] Neoantigens, also known as tumor-specific antigens (TSAs), are peptides that arise from DNA mutations in tumor cells. Unlike other tumor antigens, neoantigens are usually not present in normal tissues, making them fairly specific to cancer cells. This specificity allows the immune system to target and attack cancer cells with minimal impact on healthy cells.
[0150] In some embodiments, the epitope is a phosphopeptide, lipopeptide, or glycopeptide. In some embodiments, the epitope is modified with fatty acids, isoprenoids, sterols, phospholipids, or glycosylphosphatidylinositol.
[0151] In one embodiment, the epitope is an autoimmune peptide. The autoimmune peptide can act as an antigen, which means it can trigger an immune response. In autoimmune diseases, the immune system mistakenly targets the body’s own tissues, and autoimmune peptides may be involved in this process by being recognized as targets by the immune system. Similar to cancer antigens, autoimmune peptides are recognized by the immune system but are part of the body’s own cells. This misrecognition can lead to the immune system attacking healthy tissues, contributing to autoimmune conditions like rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. In some embodiments, the peptide is an acetylated peptide, a citrullinated peptide, a carbonylated peptide, a sulfated peptide, or a methylated peptide.
[0152] In some embodiments, the peptide comprises any one of NLVPMVATV (SEQ ID NO:39); SLYNTVATL (SEQ ID NO:44); ILKEPVHGV (SEQ ID NO:46); YLQPRTFLL (SEQ ID NO:48); CSLYQLENY (SEQ ID NO:50); LYQLENYCN (SEQ ID NO:52); RVASPTSGV (SEQ ID NO:54); RVApSPTSGV (SEQ ID NO:55); VMIGSPKKV (SEQ ID NO:60); or VMIGpSPKKV (SEQ ID NO:61), or a variant or derivative thereof. In some embodiments, the peptide comprises a sequence that is substantially identical to any one of NLVPMVATV (SEQ ID NO:39); SLYNTVATL (SEQ ID NO:44); ILKEPVHGV (SEQ ID NO:46); YLQPRTFLL (SEQ ID NO:48); CSLYQLENY (SEQ ID NO:50); LYQLENYCN (SEQ ID NO:52); RVASPTSGV (SEQ ID NO:54); RVApSPTSGV (SEQ ID NO:55); VMIGSPKKV (SEQ ID NO:60); or VMIGpSPKKV (SEQ ID NO:61). In some embodiments, the peptide comprises a sequence that has one or more amino acid substitutions as compared to any one of NLVPMVATV (SEQ ID NO:39); SLYNTVATL (SEQ ID NO:44);33185193632.1ILKEPVHGV (SEQ ID NO:46); YLQPRTFLL (SEQ ID NO:48); CSLYQLENY (SEQ ID NO:50); LYQLENYCN (SEQ ID NO:52); RVASPTSGV (SEQ ID NO:54); RVApSPTSGV (SEQ ID NO:55); VMIGSPKKV (SEQ ID NO:60); or VMIGpSPKKV (SEQ ID NO:61).
[0153] A person skilled in the art may use a number of well-known methods to determine whether a protein complex presenting an epitope affects a target cell (e.g., a T cell) in the desired manner (e.g, induction of cell activation, proliferation, anergy, or apoptosis). Applicable methods include binding assays and T cell activation assays. For example, T cell responses that can be measured for example by measuring interferon-gamma (IFNy) production, cytotoxic activity, and the like. Also, any methods disclosed in the Examples can be used.
[0154] Linkers
[0155] In some embodiments, two or more of the individual components of a protein complex are connected to each other via a linker. In some embodiments, two or more of the individual components of a protein complex are connected to each other without intervening sequences.
[0156] In one embodiment, the epitope is connected to the oxime or hydrazone linkage via a linker. In one embodiment, the MHC heavy chain (or the fragment, variant, or derivative thereof) and the beta2m polypeptide (or the fragment, variant, or derivative thereof) are connected via a linker. In one embodiment, the N-terminus of the beta2m polypeptide or fragment, variant, or derivative thereof and the oxime or hydrazone linkage are connected via a linker. In one embodiment, the Fc domain is connected to the class I MHC heavy chain or the fragment, variant, or derivative thereof via a linker. In one embodiment, a co-modulatory domain is connected to the beta2m polypeptide or the fragment, variant, or derivative thereof via a linker. In one embodiment, a co-modulatory domain is connected to the MHC heavy chain or the fragment, variant, or derivative thereof via a linker. In one embodiment, a first co-modulatory domain is connected to a second co-modulatory domain via a linker. In one embodiment, two or more co-modulatory domains are connected to each other via linkers. If a protein complex comprises more than one linker, the protein complex may comprise more than one type of linker.
[0157] Suitable linkers used herein can be of any of a number of suitable lengths, such as from 1 amino acid to 25 amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino 34185193632.1acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids. A linker may be 1, 2, 3, 4, 5, 6. 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.21.22. 23, 24, or 25 aa in length. In some cases, a linker has a length of from 25 aa to 50 aa, e.g., from 25 to 30, from 30 to 35, from 35 to 40, from 40 to 45, or from 45 to 50 aa in length.
[0158] In one embodiment, the linker is a flexible linker. Non-limiting examples of linkers include glycine polymers (G)n, glycine-serine polymers (including, for example, (GS)n(where n is an integer of at least one) or any of the linkers in Table 3), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art (see, e.g., Chichili et al., Linkers in the structural biology of protein-protein interactions. Protein Sci. 2013 Feb;22(2): 153-67, which is incorporated herein by reference in its entirety). Glycine and glycine-serine polymers can be used: both Gly and Ser are relatively unstructured and therefore can serve as a neutral tether between components. Glycine polymers can be used; glycine accesses significantly more phi-psi space than even alanine and is much less restricted than residues with longer side chains (see Scheraga, Predicting Three-Dimensional Structures of Oligopeptides. In Reviews in Computational Chemistry, John Wiley & Sons, Ltd., 1992, Vol 3; pp 73-142).
[0159] In some embodiments, the linker is a rigid linker. Rigid polypeptide linkers comprise a sequence of amino acids that effectively separates protein domains by maintaining a substantially fixed distance / spatial separation between the domains, thereby reducing or substantially eliminating unfavorable interactions between such domains. Rigid polypeptide linkers thus may be employed where it is desired to minimize the interaction between the different domains of a fusion protein. Rigid peptide linkers include, but are not limited to, peptide linkers rich in proline, and peptide linkers having an inflexible helical structure, such as an a-helical structure.
[0160] Flexible or rigid linkers can be used, or a combination thereof. Provided herein are also linkers that are combinations or that contain repeats of any of the linkers disclosed herein.
[0161] In some embodiments, the linker comprises any one of SEQ ID NOs:28-38, or variants, derivatives, or combinations thereof.
[0162] Linkers, including the polypeptide linkers described herein, may be present between a payload coupled to a protein complex.
[0163] Other linkers that can be used with the compositions and methods disclosed herein include non-peptide linkers, such as polymers comprising, for example, polyethylene glycol 35185193632.1(PEG). Other linkers, including those resulting from coupling with a bifunctional crosslinking agent, may also be utilized. In one embodiment, the linker is an amino acid polymer hybrid linker.
[0164] Signal Peptides
[0165] The polypeptides disclosed herein may be expressed with a signal peptide, also referred to herein as a signal sequence. Sequences of suitable signal peptides are known in the art. A person skilled in the art may employ any signal sequence compatible with the compositions and methods disclosed herein. See. e.g, Owji et al., A comprehensive review of signal peptides: Structure, roles, and applications. Eur J Cell Biol. 2018 Aug;97(6):422-441; O'Neill P, Mistry RK, Brown AJ, James DC. Protein-Specific Signal Peptides for Mammalian Vector Engineering. ACS Synth Biol. 2023 Aug 18;12(8):2339-2352, which are incorporated herein by reference in their entireties.
[0166] Epitope Tags and Affinity Domains
[0167] The protein complexes and MHC scaffolds may be fused to an epitope tag or affinity domain, e.g.. for detection and / or for purification. Suitable epitope tags include, but are not limited to, hemagglutinin (HA; e.g., YPYDVPDYA (SEQ ID NO: 66)); c-myc (e.g., EQKLISEEDL; SEQ ID NO: 67)), and the like. Affinity domains include peptide sequences that can interact with a binding partner, e.g., such as one immobilized on a solid support, useful for identification or purification. DNA sequences encoding multiple consecutive single amino acids, such as histidine, when fused to the expressed protein, may be used for one-step purification of the recombinant protein by high affinity binding to a resin column, such as nickel SEPHAROSE®. Illustrative affinity domains include His5 (HHHHH) (SEQ ID NO:68), HisX6 (HHHHHH) (SEQ ID NO:69), C-myc (EQKLISEEDL) (SEQ ID NO:70), Flag (DYKDDDDK) (SEQ ID NO:71). StrepTag (WSHPQFEK) (SEQ ID NO:72), hemagglutinin, (e.g, HA Tag (YPYDVPDYA) (SEQ ID NO:73)), glutathione-S-transferase (GST), thioredoxin, cellulose binding domain, RYIRS (SEQ ID NO:74), Phe-His-His-Thr (SEQ ID NO: 75), chitin binding domain, S-peptide, T7 peptide, SH2 domain, C-end RNA tag, WEAAAREACCRECCARA (SEQ ID NO:76), metal binding domains, e.g., zinc binding domains or calcium binding domains such as those from calcium-binding proteins, e.g, calmodulin, troponin C, calcineurin B, myosin light chain, recoverin, S-modulin, visinin, VILIP, neurocalcin, hippocalcin, frequenin, caltractin, calpain large-subunit, S100 proteins,36185193632.1parvalbumin, calbindin D9K, calbindin D28K, and calretinin, inteins, biotin, streptavidin, MyoD. Id, leucine zipper sequences, and maltose binding protein.
[0168] Fusion to Functional Moieties
[0169] In some embodiments, the protein complex or MHC scaffold is conjugated to a functional moiety, including, but not limited to, a diagnostic moiety, a detectable moiety,, a therapeutic moiety, or a moiety’ useful for purification.
[0170] Examples of moieties useful for purification include, but are not limited to. Albumin-binding protein (ABP), Alkaline Phosphatase (AP), AU1 epitope, AU5 epitope, Bacteriophage T7 epitope (T7-tag), Bacteriophage V5 epitope (V5-tag), Biotin-carboxy carrier protein (BCCP), Bluetongue virus tag (B-tag), Calmodulin binding peptide (CBP), Chloramphenicol Acetyl Transferase (CAT), Cellulose binding domain (CBD). Chitin binding domain (CBD), Choline-binding domain (CBD), Dihydrofolate reductase (DHFR), E2 epitope, FLAG epitope, Galactose-binding protein (GBP), Green fluorescent protein (GFP), Glu-Glu (EE-tag), Glutathione S-transferase (GST), Human influenza hemagglutinin (HA), HaloTag®, Histidine affinity tag (HAT), Horseradish Peroxidase (HRP), HSV epitope. Ketosteroid isomerase (KSI), KT3 epitope, LacZ, Luciferase, Maltose-binding protein (MBP), Myc epitope, NusA, PDZ domain, PDZ ligand, Polyarginine (Arg-tag), Polyaspartate (Asp-tag), Polycysteine (Cys-tag), Polyhistidine (His-tag), Polyphenylalanine (Phe-tag), Profinity eXact, Protein C, Sl-tag, S-tag, Streptavadin-binding peptide (SBP), Staphylococcal protein A (Protein A), Staphylococcal protein G (Protein G). Strep-tag, Streptavadin, Small Ubiquitin-like Modifier (SUMO), Tandem Affinity Purification (TAP), T7 epitope, Thioredoxin (Trx), TrpE, Ubiquitin, Universal, and VSV-G.
[0171] Examples of detectable moieties include, but are not limited to, fluorescent moieties or labels, imaging agents, radioisotopic moieties, radiopaque moieties, and the like, e.g., detectable labels such as biotin, fluorophores, chromophores, spin resonance probes, positron emission tomography (PET) imaging reagents or radiolabels. Non-limiting examples of fluorophores include fluorescent dyes (e.g., fluorescein, rhodamine, and the like) and other luminescent molecules (e.g.. luminal). A fluorophore may be environmentally-sensitive such that its fluorescence changes if it is located close to one or more residues in the modified protein that undergo structural changes upon binding a substrate (e.g, dansyl probes). Non-limiting examples of radiolabels include small molecules containing atoms with one or more low sensitivity' nuclei (13C,15N,2H,125I,123I,99mTc,43K,52Fe,67Ga,68Ga, "’in, and the like). Non- 37185193632.1limiting examples of PET imaging reagents include small molecules and chelators containing atoms with appropriate nuclei (18F,64Cu,89Zr, and the like). Other useful moieties are known in the art.
[0172] Examples of diagnostic moieties include, but are not limited to, detectable moieties suitable for revealing the presence of a disease or disorder. Typically, a diagnostic moiety allows for determining the presence, absence, or level of a molecule, for example, a target peptide, protein, or proteins, that is associated with a disease or disorder. Such diagnostics are also suitable for prognosing and / or diagnosing a disease or disorder and its progression.
[0173] Examples of therapeutic moieties include, but are not limited to, anti-inflammatory agents, anti-cancer agents, anti-neurodegenerative agents, anti-infective agents, or generally a therapeutic moiety. The functional moiety may also have one or more of the herein-mentioned functions.
[0174] Non-limiting examples of therapeutic moieties include radionuclides with high-energy ionizing radiation that are capable of causing multiple strand breaks in nuclear DNA, and therefore suitable for inducing cell death (e.g., of a cancer cell). Non-limiting examples of high-energy radionuclides include:90Y,125I,131I,123I,111In,105Rh,153Sm,67Cu,67Ga,166Ho,177LU,186Re,225Ac, and188Re. These isotopes typically produce high-energy a- or 0-particles which have a short path length. Such radionuclides kill cells to which they are in close proximity, for example neoplastic cells to which the conjugate has attached or has entered. They have little or no effect on non-localized cells and are essentially non-immunogenic.
[0175] Non-limiting examples of therapeutic moieties also include cytotoxic agents such as cytostatics (e.g., alkylating agents, DNA synthesis inhibitors, DNA-intercalators or crosslinkers, or DNA-RNA transcription regulators), enzyme inhibitors, gene regulators, cy totoxic nucleosides, tubulin binding agents, hormones and hormone antagonists, anti-angiogenesis agents, and the like.
[0176] Non-limiting examples of therapeutic moieties also include alkylating agents such as the anthracycline family of drugs (e.g., adriamycin, carminomycin, cyclosporin-A, chloroquine, methopterin, mithramycin, porfiromycin. streptonigrin, anthracenediones, and aziridines). In another embodiment, the chemotherapeutic moiety is a cytostatic agent such as a DNA synthesis inhibitor. Examples of DNA synthesis inhibitors include, but are not limited to, methotrexate and di chloromethotrexate, 3-amino-l,2,4-benzotriazine 1,4-di oxide, aminopterin, cytosine 0-D-arabinofuranoside, 5-fluoro-5'-deoxyuridine, 5-fluorouracil,38185193632.1ganciclovir, hydroxyurea, actinomycin-D, and mitomycin C. Non-limiting examples of DNA-intercalators or cross-linkers include, but are not limited to, bleomycin, carboplatin, carmustine, chlorambucil, cyclophosphamide, cis-diammineplatinum(II) dichloride (cisplatin), melphalan, mitoxantrone, and oxaliplatin.
[0177] Non-limiting examples of therapeutic moieties also include transcription regulators such as actinomycin D, daunorubicin, doxorubicin, homoharringtonine, and idarubicin. Other non-limiting examples of cytostatic agents that are compatible with the embodiments disclosed herein include ansamycin benzoquinones, quinonoid derivatives (e.g., quinolones, genistein, bactacyclin), busulfan, ifosfamide, mechlorethamine, triaziquone, diaziquone, carbazilquinone, indoloquinone EO9, diaziridinyl-benzoquinone methyl DZQ, triethylenephosphoramide, and nitrosourea compounds (e.g.. carmustine, lomustine, semustine).
[0178] Non-limiting examples of therapeutic moieties also include cytotoxic nucleosides such as, for example, adenosine arabinoside, cytarabine, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, ftorafur, and 6-mercaptopurine; tubulin binding agents such as taxoids e.g., paclitaxel, docetaxel, taxane), nocodazole, rhizoxin, dolastatins (e.g., Dolastatin-10, -11, or -15), colchicine and colchicinoids (e.g., ZD6126), combretastatins (e.g., Combretastatin A-4, AVE-6032), and vinca alkaloids (e.g., vinblastine, vincristine, vindesine, and vinorelbine (navelbine)); anti-angiogenesis compounds such as Angiostatin K.l-3, DL-a-difluoromethyl-omithine, endostatin, fumagillin, genistein, minocycline, staurosporine, and (±)-thalidomide.
[0179] Non-limiting examples of therapeutic moieties also include hormones and hormone antagonists, such as corticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone or medroxyprogesterone), estrogens (e.g., diethylstilbestrol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone), aromatase inhibitors (e.g, aminogluthetimide). 17-(allylamino)-17-demethoxygeldanamycin, 4-amino-l,8-naphthahmide, apigenin, brefeldin A, cimetidine, dichloromethylene-diphosphonic acid, leuprolide (leuprorelin), luteinizing hormone-releasing hormone, pifithrin-a, rapamycin, sex hormone-binding globulin, and thapsigargin.
[0180] Non-limiting examples of therapeutic moieties also include enzyme inhibitors such as, S(+)-camptothecin. curcumin, (-)-deguelin, 5,6-dichlorobenz-imidazole 1-J3-D-ribofuranoside, etoposide, formestane, fostriecin, hispidin, 2-imino-l-imidazolidineacetic acid (cyclocreatine), mevinolin, trichostatin A, tyrphostin AG 34, and tyrphostin AG 879.39185193632.1
[0181] Non-limiting examples of therapeutic moieties also include gene regulators such as 5-aza-2'-deoxycytidine, 5 -azacytidine, cholecalciferol (vitamin D3). 4-hydroxytamoxifen, melatonin, mifepristone, raloxifene, trans-retinal (vitamin A aldehydes), retinoic acid, vitamin A acid, 9-cis-retinoic acid, 13-cis-retinoic acid, retinol (vitamin A), tamoxifen, and troglitazone.
[0182] Non-limiting examples of therapeutic moieties also include cytotoxic agents such as, for example, the pteridine family of drugs, diynenes, and the podophyllotoxins. Particularly useful members of those classes include, for example, methopterin, podophyllotoxin, or podophyllotoxin derivatives such as etoposide or etoposide phosphate, leurosidine, vindesine, leurosine and the like.
[0183] Still other cytotoxins that are compatible with the teachings herein include auristatins (e.g., auristatin E and monomethyl auristan E), calicheamicin, gramicidin D, maytansanoids (e.g., maytansine), neocarzinostatin, topotecan, taxanes, cytochalasin B, ethidium bromide, emetine, tenoposide, colchicin, dihydroxy anthracindione, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs thereof.
[0184] A moiety may have more than one function.
[0185] Of note, the individual components of a protein complex and an MHC scaffold (e.g., linkers, signal peptides, affinity tags, functional moieties, MHC heavy chain, beta2m chain, backbone polypeptide, and co-modulatory domain(s)) can be arranged in any orientation (e.g., component A is N-terminal or C-terminal of component B) that does not abolish the function of the individual components. For example, one or more co-modulatory domains can be attached at multiple attachment sites, including at the C-terminus of the Fc segment, the N-terminus of the MHC heavy chain, and the C-terminus of the beta2m. Possible arrangements include, but are not limited to, the arrangements shown in Fig. 1, Fig. 2, and Fig. 3.
[0186] In one embodiment, the MHC heavy chain or the fragment, variant, or derivative thereof and the beta2m polypeptide or the fragment, variant, or derivative thereof are part of a continuous amino acid chain. In one embodiment, the MHC heavy chain or the fragment, variant, or derivative thereof, and the beta2m polypeptide or the fragment, variant, or derivative thereof are connected through a linker. In one embodiment, provided is a polypeptide comprising from N- to C-terminus: (1) beta2m polypeptide or a fragment, variant, or derivative thereof; (2) optionally, a linker; (3) MHC heavy chain or a fragment,40185193632.1variant, or derivative thereof; (4) optionally, a linker; (5) Fc segment; (6) optionally, a linker; (7) one or more co-modulatory domains.
[0187] Oxime and Hydrazone Coupling
[0188] Provided herein are protein complexes comprising epitopes that are linked to an MHC complex via an oxime or hydrazone linkage. As used herein, an “oxime linkage” is a covalent connection between two molecules created by oxime coupling, and a “hydrazone linkage” is a covalent connection between two molecules created by hydrazone coupling.
[0189] Oxime coupling (also referred to as aldehyde-alkoxyamine chemistry) is a chemical reaction that involves the formation of an oxime bond between a carbonyl compound (such as an aldehyde or ketone) and a hydroxylamine derivative. It is a versatile bio-orthogonal conjugation strategy that benefits from high chemo-selectivity and regio-selectivity, mild reaction conditions, and hydrolytic stability of the resultant oxime bond.
[0190] Provided herein is a method of making a protein complex comprising (a) an MHC complex comprising (i) a class I major histocompatibility (MHC) polypeptide or a fragment, variant, or derivative thereof, and (ii) a beta2m polypeptide or a fragment, variant, or derivative thereof and (b) an epitope, the method comprising:(a) oxidizing the N-terminal amino acid of the beta2m polypeptide or fragment, variant, or derivative thereof, to form an aldehyde at the N-terminal position of the beta2m polypeptide or fragment, variant, or derivative thereof, wherein the N-terminal amino acid is serine or threonine;(b) reacting the aldehyde formed in step (a) with a primary amine catalyst to form a Schiff base; and(c) reacting the Schiff base formed in step (b) w ith an epitope comprising a functional groupthe protein complex,wherein in the protein complex, the epitope is coupled to the N-terminus of the beta2m polypeptide or the fragment, variant, or derivative thereof via an oxime linkage.41185193632.1
[0191] In embodiments, in step (a), the N-terminal amino acid on the beta2m polypeptide or fragment, variant, or derivative thereof is reacted with a suitable oxidizing agent. In some embodiments, the oxidizing agent is sodium periodate (NaIO₄), lead tetraacetate (Pb(OAc)4), or potassium perruthenate (KRuO₄). In some embodiments, the N-terminal amino acid is anN-terminal serine or an N-terminal threonine.
[0192] In some embodiments, the oxidation reaction in step (a) occurs at room temperature. In some embodiments, the time to complete the oxidation reaction of step (a) is about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes, about 15 minutes, or any range between any two of the aforementioned time values. In some embodiments, the oxidation reaction in step (a) occurs at a pH of about 6.0. about 6.5, about 7.0, about 7.5, about 8.0, or any range between any two of the aforementioned values.
[0193] In one embodiment, in step (b), the aldehyde formed in step (a) is reacted with a primary amine to form a Schiff base. The term “Schiff base” is meant to extend to all protein or polypeptide derivatives exhibiting a > C=N — functionality and thus also encompasses compounds, such as oximes.
[0194] In some embodiments, the primary amine is an aniline derivative. In some embodiments, the primary amine is selected from the group consisting of benzamide, phenylene diamine, o-toluidine, m-toluidine. p-toluidine, o-anisidine, m-anisidine. and p-anisidine. In some embodiments, the primary amine is a derivative of benzamide, phenylene diamine, o-toluidine, m-tolui dine, p-toluidine, o-anisidine, m-anisidine, and p-anisidine.
[0195] In one embodiment, in step (c), the Schiff base formed in step (b) is reacted with an epitope comprising a functional group selected from the group consisting of:the protein complex. In some embodiments, the epitope comprises a peptide sequence selected from Table 4.
[0196] In one embodiment, the epitope and the functional group are connected via a linker. In some embodiments, the N-terminal amino-acid on the beta2m and the rest of the beta2m are connected via a linker. In some embodiments, the linker is a glycine-rich linker. In some embodiments, the glycine rich linker comprises serine. In some embodiments, the 42185193632.1glycine rich linker is a GGG, ( -IS)2. or (G4S)s or any other linker, including a linker disclosed herein.
[0197] In one embodiment, steps (b) and (c) are performed consecutively in the same reaction vessel without isolation of the Schiff base formed in step (b). In some embodiments, the primary amine added in step (a) is catalytically recycled in step (c).
[0198] In some embodiments, the steps (b) and (c) occur at room temperature. In some embodiments, steps (b) and (c) occur at about 3 °C. at about 4 °C, at about 5 C, at about 6 °C, at about 7 °C, at about 8 °C, at about 9 °C, at about 10 °C, about 11 °C, about 12 °C, about 13 °C, about 14 °C, about 15 °C, about 16 °C, about 17 °C, about 18 °C, about 19 °C, about 20 °C, about 21 °C, about 22 °C, about 23 °C, about 24 °C, about 25 °C, about 26 °C, about 27 °C, about 28 °C, about 29 °C, about 30 °C. about 31 °C, about 32 °C, about 33 °C, about 34 °C, about 35 °C, about 36 °C, about 37 °C, about 38 °C, about 39 °C, or about 40 °C.
[0199] In some embodiments, the time to complete steps (b) and (c) is about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes, about 15 minutes, 60 minutes, about 90 minutes, about 120 minutes, about 150 minutes, about 180 minutes, or any range between any two of the aforementioned time values. In some embodiments, steps (b) and (c) are performed in several hours. In some embodiments, steps (b) and (c) are performed in about 12 hours.
[0200] In some embodiments, the reaction in steps (b) and (c) occurs at a pH of about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, or any range between any two of the aforementioned values.
[0201] In some embodiments, aldehyde-hydrazino / hydrazide chemistry may be used instead to link the peptide to the MHC. In one embodiment, in step (c), the Schiff base formed in step (b) is reacted with an epitope comprising a functional group comprising a hydrazino or a hydrazide, to form the protein complex, wherein in the protein complex, the epitope is coupled to the N-terminus of the beta2m polypeptide or the fragment, variant, or derivative thereof via a hydrazone linkage. In some embodiments, the functional group comprising the hydrazino or the hydrazide is selected from43185193632.1
[0202] In some embodiments, the epitope comprises a peptide sequence selected from Table 4
[0203] Nucleic Acids
[0204] Also provided herein are nucleic acid sequences encoding a polypeptide disclosed herein. Further provided are vectors comprising such nucleic acids and host cells comprising such nucleic acids or vectors.
[0205] The term "‘nucleic acid” as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes, but is not limited to, single-, double- or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.
[0206] Provided herein is a nucleic acid that encodes a protein complex disclosed herein (or a portion thereof) or an MHC scaffold disclosed herein (or a portion thereof). The nucleic acids disclosed herein may be DNA, cDNA, RNA, synthetically produced DNA or RNA, or a recombinantly produced chimeric nucleic acid molecule comprising any of those polynucleotides either alone or in combination.
[0207] ‘’Vector” means a recombinant plasmid, yeast artificial chromosome (Y AC), mini chromosome, DNA mini-circle or virus (including virus derived sequences) that comprises a polynucleotide to be delivered into a host cell, either in vitro or in vivo. A “vector” includes, but is not limited to. a viral vector, a plasmid, an RNA vector or a linear or circular DNA or RNA molecule which may consist of chromosomal, non-chromosomal, semi-synthetic or synthetic nucleic acids. In some embodiments, the employed vectors are those capable of autonomous replication (episomal vector) and / or expression of nucleic acids to which they are linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and are commercially available. The vector can be a lipid nanoparticle comprising a nucleic acid such as mRNA.
[0208] Also provided herein are vectors comprising nucleic acids disclosed herein.185193632.1
[0209] Suitable expression vectors include, but are not limited to, viral vectors (e.g, viral vectors based on vaccinia virus; poliovirus; adenovirus; adeno-associated virus; SV40; herpes simplex virus; human immunodeficiency virus; a retrovirus (e.g, Murine Leukemia Virus, spleen necrosis virus, Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus); and the like. Numerous suitable expression vectors are known to those of skill in the art, and many are commercially available. The following vectors are provided by way of example for eukaryotic host cells: pXTl, pSG5 (Stratagene®), pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia). However, any other vector may be used so long as it is compatible with the host cell.
[0210] Depending on the host / vector system utilized, any of a number of suitable transcription and translation control elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc., may be used in the expression vector.
[0211] In some embodiments, a nucleotide sequence encoding a polypeptide disclosed herein is operably linked to a control element, e.g., a transcriptional control element, such as a promoter. The transcriptional control element may be functional in either a eukaryotic cell, e.g., a mammalian cell, or an insect cell, or a fungal cell; or a prokaryotic cell (e.g., bacterial or archaeal cell). In some embodiments, a nucleotide sequence encoding a polypeptide disclosed herein is operably linked to multiple control elements that allow expression of the nucleotide sequence encoding the polypeptide disclosed herein in both prokaryotic and eukaryotic cells.
[0212] Non-limiting examples of suitable eukaryotic promoters (promoters functional in a eukaryotic cell) include those from cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, early and late SV40, long terminal repeats (LTRs) from retroviruses, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector may also contain a ribosome binding site for translation initiation and a transcription terminator. The expression vector may also include appropriate sequences for amplifying expression.
[0213] Provided is a host cell comprising a nucleic acid molecule described herein, or a vector described herein.45185193632.1
[0214] Suitable host cells include eukaryotic cells, such as yeast cells, insect cells, and mammalian cells. In some cases, the host cell is a cell of a mammalian cell line. Suitable mammalian cell lines include human cell lines, non-human primate cell lines, rodent e.g., mouse, rat) cell lines, and the like. Suitable mammalian cell lines include, but are not limited to, HeLa cells (e.g., American Type Culture Collection (ATCC) No. CCL-2™), CHO cells (e.g, ATCC Nos. CRL-9618™, CCL-61™, CRL9096), 293 cells (e.g., ATCC No. CRL-1573™). Vero cells, NIH 3T3 cells (e.g, ATCC No. CRL-1658), Huh-7 cells, BHK cells (e.g. ATCC No. CCL-10™), PC12 cells (ATCC No. CRL-1721™), COS cells, COS-7 cells (ATCC No. CRL1651), RATI cells, mouse L cells (ATCC No. CCLI.3), human embryonic kidney (HEK) cells (ATCC No. CRL1573), HLHepG2 cells, and the like.
[0215] In some cases, the host cell is a mammalian cell that has been genetically modified such that it does not synthesize endogenous MHC beta2m and / or such that it does not synthesize endogenous MHC Class I heavy chains.
[0216] The cell can be isolated. The cell may be a mammalian cell. The cell may be human.
[0217] Pharmaceutical Compositions
[0218] In one embodiment, provided herein is a pharmaceutical composition comprising a protein complex or an MHC scaffold disclosed herein and a pharmaceutically acceptable carrier.
[0219] Pharmaceutically-acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. The pharmaceutical compositions may generally be formulated in full compliance with all Good Manufacturing Practice (GMP) regulations of the U. S. Food and Drug Administration.
[0220] The terms “pharmaceutically acceptable,” “physiologically tolerable,” as referred to compositions, carriers, diluents, and reagents, are used interchangeably and include materials that are capable of administration to or upon a subject without the production of undesirable physiological effects to the degree that would prohibit administration of the composition. For example, “pharmaceutically-acceptable excipient” includes an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use.46185193632.1
[0221] Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin. The use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the compositions disclosed herein, use of the media or compound in the compositions disclosed herein is contemplated. In some embodiments, a second therapeutic agent, such as an anti-cancer or anti-tumor, can also be incorporated into pharmaceutical compositions.
[0222] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water-soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N. J.) or phosphate-buffered saline (PBS). The composition may be sterile and fluid to the extent that easy syringeability exists. In embodiments, the compositions disclosed herein are stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, e.g, water, ethanol, polyol (e.g, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, e.g., by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
[0223] In some embodiments, the pharmaceutical composition further includes a cryoprotectant (e.g., glycerol, DMSO, PEG).
[0224] In some embodiments, the pharmaceutical composition will be suitable for administration to a subject, e.g., will be sterile. For example, in some embodiments, a subject pharmaceutical composition will be suitable for administration to a human subject, e.g, where the composition is sterile and is free of detectable pyrogens and / or other toxins and / or such detectable pyrogens and / or other toxins are below permissible limits.
[0225] Where a composition disclosed herein is administered as an injectable (e.g, subcutaneously, intraperitoneally, intramuscularly, and / or intravenously) directly into a tissue, a formulation can be provided as a ready -to-use dosage form, a non-aqueous form (e.g, a reconstitutable storage-stable powder) or an aqueous form, such as liquid composed of pharmaceutically acceptable carriers and excipients. The formulations comprising a protein complex or an MHC scaffold disclosed herein may also be provided so as to enhance serum 47185193632.1half-life of the subject protein following administration. For example, the protein complex or MHC scaffold may be provided in a liposome formulation, prepared as a colloid, or other conventional techniques for extending serum half-life. A variety of methods for preparing liposomes are known in the art. The preparations may also be provided in controlled release or slow-release forms.
[0226] Other examples of formulations suitable for parenteral administration include isotonic sterile injection solutions, antioxidants, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. For example, a pharmaceutical composition can be present in a container, e.g, a sterile container, such as a syringe. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
[0227] The concentration of a protein complex or an MHC scaffold in a formulation can vary widely (e.g., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight) and will usually be selected primarily based on fluid volumes, viscosities, and patient-based factors in accordance with the particular mode of administration selected and the patient's needs.
[0228] Methods
[0229] Provided herein are methods of using the compositions disclosed herein. The protein complexes and MHC scaffolds described herein can be used for various therapeutic applications (in vivo and ex vivo) and as research tools, e.g., in vitro and animal model systems. The protein complex may comprise one or more co-modulatory domains.
[0230] Provided herein are methods of modulating the activity of T cells or NK cells, including cytotoxic T cells. Modulation can include promoting or reducing T cell or NK cell activation / activity.
[0231] Provided herein is a method of modulating the activity of a T cell or an NK cell with a T cell receptor (TCR), the method comprising contacting the T cell or NK cell with a protein complex disclosed herein, wherein the protein complex comprises an epitope (or with a pharmaceutical composition comprising a protein complex disclosed herein), wherein the TCR of the T cell or NK cell binds to the epitope presented by the protein complex. As such,48185193632.1provided herein is a method of selectively modulating the activity of an epitope-specific T cell, the method comprising contacting the T cell or NK cell with a protein complex bearing the epitope recognized by the epitope-specific T cell orNK cell, where contacting the T cell orNK cell with the protein complex selectively modulates the activity of the epitope-specific T cell or NK cell. The protein complex may comprise one or more co-modulatory domains. In one embodiment, the contacting occurs in vitro. In one embodiment, the contacting occurs in vivo. In one embodiment, the contacting occurs ex vivo.
[0232] ‘’Activation of a T cell” may refer to induction of signal transduction pathways in the T cell resulting in production of cellular products (.g., interleukin-2) by that T cell. Methods of measuring T cell activation are known in the art. See. e.g., Phetsouphanh et al., Detecting Antigen-Specific T Cell Responses: From Bulk Populations to Single Cells. Int J Mol Sci. 2015 Aug 12; 16(8): 18878-93, which is incorporated herein by reference in its entirety. T cell activation can be measured, for example, by detecting activation marker CD25 by flow cytometry. Activation can also be measured by, for example, measuring the amount of IL-2 produced by a T cell after a peptide / MHC complex has bound to the TCR. T cell activation may be determined, e.g., by measuring changes in the level of expression of cytokines and / or T cell activation markers, and / or the induction of antigen-specific proliferating cells. Techniques known to those of skill in the art, including, but not limited to, immunoprecipitation followed by Western blot analysis, ELISAs, flow cytometry, Northern blot analysis, and RT-PCR can be used to measure the expression of cytokines and T cell activation markers. Cytokine release may be measured by measuring secretion of cytokines including, but not limited to, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-6 (IL-6), Interleukin- 12 (IL-12), Interleukin- 16 (IL-16), PDGF, TGF-alpha, TGF-beta, TNF-alpha, TNF-beta. GCSF, GM-CSF, MCSF. IFN-alpha. IFN-beta, IFN-gamma, TFN-gamma, IGF-I, and IGF-II. Methods of NK cell activation are also known in the art.
[0233] Where a protein complex comprises a co-modulatory domain that is an activating polypeptide, contacting the T cell or NK cell with the protein complex activates the epitopespecific T cell or NK cell. As such, provided herein is a method of enhancing the activity of a T cell or NK cell with a TCR, the method comprising contacting the T cell or NK cell with a protein complex comprising an epitope and a co-modulatory domain that promotes T cell or NK cell activation (or with a pharmaceutical composition comprising such a protein complex), wherein the TCR of the T cell or NK cell binds to the epitope.49185193632.1
[0234] Where a protein complex comprises a co-modulatory domain that is an inhibiting polypeptide, contacting the T cell with the protein complex inhibits the epitope-specific T cell or NK cell. As such, provided herein is a method of reducing the activity of a T cell or NK cell with a TCR, the method comprising contacting the T cell or NK cell with a protein complex comprising an epitope and a co-modulatory domain that inhibits T cell or NK cell activation (or with a pharmaceutical composition comprising such a protein complex), wherein the TCR of the T cell or NK cell binds to the epitope.
[0235] A T cell or NK cell population of interest (e.g., the T cell or NK cell population that the person skilled in the art wishes to expand) may specifically bind to the epitope displayed by a protein complex disclosed herein (wherein the epitope is displayed in the context of the particle's MHC). As such, provided herein is a method of expanding a population of T cells each comprising a TCR, the method comprising contacting the population of T cells or NK cells with a protein complex disclosed herein (or with a pharmaceutical composition comprising such a protein complex), wherein the TCR of the T cells or NK cells binds to the epitope presented by the protein complex. Provided herein is a method of expanding a population of T cells or NK cells each comprising a TCR, the method comprising contacting the population of T cells or NK cells with a protein complex comprising an epitope and one or more co-modulatory domains that promote T cell or NK cell expansion (or with a pharmaceutical composition comprising such a protein complex), wherein the TCR of the T cells or NK cells binds to the epitope presented by the protein complex. The T cells or NK cells may further be exposed to one or more cytokines that enhance selective differentiation and / or expansion. The expansion may take place in vitro (for production of cells for adoptive T cell or NK cell therapy involving TCR T cells and TCR NK cells, respectively) and in vivo (e.g., for durability of adoptive cell therapy involving TCR T cells and TCR NK cells).
[0236] In some embodiments, the activated T cells or NK cells are further cultured. The term ’‘culturing” or “expanding” refers to maintaining or cultivating cells under conditions in which they can proliferate and avoid senescence. For example, cells may be cultured in media optionally containing one or more growth factors, i.e., a growth factor cocktail. In some embodiments, the cell culture medium is a defined cell culture medium. The cell culture medium may include neoantigen peptides. Stable cell lines may be established to allow for the continued propagation of cells.50185193632.1
[0237] Provided is a method of inducing expression of pro-inflammatory cytokines in a T cell or an NK cell comprising a TCR, the method comprising contacting the T cell or NK cell with a protein complex disclosed herein (or with a pharmaceutical composition comprising such a protein complex), wherein the TCR of the T cells or NK cells binds to the epitope presented by the protein complex.
[0238] Methods of measuring pro-inflammatory cytokines and activation markers are known in the art. For example, pro-inflammatory cytokines include, but are not limited, to IL-1, IL-2, IL-6, IL-8, IL-12, IL-17, IL-18, IFN-gamma, TNF-alpha, perforin, and granzyme B. Expression of these cytokines can be measured on the nucleic acid level (e.g., by RT-PCR) or on the protein level (e.g., by ELISA).
[0239] The methods disclosed herein may be performed in vitro, in vivo, or ex vivo. Merely to illustrate, in one embodiment, the method of activating or expanding a T cell or NK cell comprising a TCR is performed in vivo by administering to a patient a protein complex disclosed herein, wherein the protein complex activates the patient’s own T cells or NK cells that bind to the epitope presented on the protein complex. In one embodiment, the method is performed ex vivo by removing T cells or NK cells from a patient, activating the patient’s own T cells or NK cells that bind to the epitope presented on the protein complex, optionally expanding the activated T cells or NK cells, optionally washing the activated T cells or NK cells, and reintroducing the activated T cells or NK cells into the same patient or a different patient. In another embodiment, the T cells or NK cells are activated in vitro by contacting the T cells or NK cells with the protein complex.
[0240] In some embodiments, the T cells or NK cells are autologous, allogeneic, syngeneic, or xenogeneic.
[0241] T cells to be used in the methods disclosed herein can be obtained from several sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infection site, ascites, pleural effusion, splenic tissue, and tumors. T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the person skilled in the art. such as the separation using a neutral, highly branched, high-mass, hydrophilic polysaccharide which dissolves readily in aqueous solutions. Circulating blood cells of an individual are obtained by apheresis. The apheresis product typically contains lymphocytes, including T lymphocytes, monocytes, granulocytes, B lymphocytes, other nucleated white blood cells, red blood cells, and platelets.51185193632.1The cells harvested by apheresis can be washed to remove the plasma fraction and place the cells in a suitable buffer or medium for the subsequent processing steps. The cells may be washed with phosphate-buffered saline (PBS). Alternatively, the wash solution may lack calcium and may lack magnesium or may lack many, if not all, divalent cations. As those of ordinary skill in the art would readily appreciate, a washing step can be achieved by methods known to those skilled in the art, such as using a semiautomatic continuous flow centrifuge. After washing, the cells can be resuspended in a variety of biocompatible buffers, such as, for example, Ca2+free, PBS free Mg2+, PlasmaLyte A, or other saline solution with or without buffer. Alternatively, the undesirable components of the apheresis sample can be removed, and the cells resuspended directly in a culture medium.
[0242] As described herein, T cells may be isolated from peripheral blood by lysis of red blood cells and depletion of monocytes, for example, by density gradient centrifugation or by countercurrent centrifugal elutriation. T cells may also be isolated from the spleen. T cells may be isolated by incubation with conjugated anti-CD3 beads for a sufficient period of time (i.e., 30 minutes to 24 hours) for positive selection of the desired T lymphocytes. For the isolation of T lymphocytes from patients with leukemia, the use of longer incubation times, such as 24 hours, can increase cellular performance. Longer incubation times can be used to isolate T lymphocytes in any situation where there are few T lymphocytes compared to other cell types, such as isolating tumor-infiltrating lymphocytes (TILs) from tumor tissue or from immunocompromised individuals. The person skilled in the art will recognize that multiple rounds of selection may also be used. It may be desirable to perform the selection procedure and use the “unselected” cells in the activation and expansion process. “Unselected” cells can also undergo new rounds of selection.
[0243] Enrichment of a population of T cells or NK cells by negative selection can be performed with a combination of antibodies directed to unique surface markers for the negatively selected cells. One method is the sorting and / or selection of cells by positive or negative magnetic immune adherence or flow cytometry using a cocktail of monoclonal antibodies directed to cell surface markers present in the negatively selected cells. Alternatively, the regulatory T lymphocytes are depleted by anti-CD25 conjugate beads or other similar selection method.
[0244] T cells or NK cells can also be frozen after a washing step. Wishing not to be bound by theory', freezing and the following thawing step provide a more uniform product by 52185193632.1eliminating granulocytes and, to some extent, monocytes in the cell population. After the washing step that removes the plasma and platelets, the cells can be suspended in a freezing solution. Although many solutions and freezing parameters are known in the art and will be useful in this context, one method involves the use of PBS containing 20% DMSO and 8% human serum albumin, or culture medium containing 10% dextran 40 and 5% dextrose and human albumin and 7.5% DMSO or 31.25% Plasmalyte A, 31.25% dextrose 5%, 0.45% NaCl, 10% dextran 40 and 5% of dextrose, 20% serum of human albumin and 7.5% of DMSO or other suitable cell freezing medium containing, for example, Hespan and PlasmaLyte A. The cells may then be frozen at -80 °C at a rate of 1 °C per minute and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing can be used.
[0245] The cryopreserved cells may be thawed and washed as described herein and allowed to stand for one hour at room temperature before activation using the methods disclosed herein. As described herein, T cells or NK cells can be expanded, frozen, and used later. As described herein, samples may be collected from a patient shortly after the diagnosis of a particular disease as described herein, but before any treatment. The cells may be isolated from a blood sample or an apheresis of a subject before any number of relevant treatment modalities, including but not limited to, treatment with agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, radiation, immunosuppressive agents such as cyclosporine, azathioprine, methotrexate, my cophenolate, and FK506, antibodies or other immunoablatories such as CAMPATH. anti-CD3 antibodies, cytoxan, fludarabine, cyclosporin. FK506, rapamycin, mycophenolic acid, steroids, FR901228, and irradiation.
[0246] Provided herein is a method of detecting, in a mixed population of cells (<?.g., a mixed population of T cells or NK cells) obtained from an individual, the presence of a target T cell or NK cell that binds an epitope of interest, the method comprising: (a) contacting in vitro the mixed population of cells (e.g., mixed population of T cells or NK cells) with a protein complex comprising the epitope of interest; and (b) detecting activation and / or proliferation of T cells orNK cells in response to said contacting, wherein activated and / or proliferated T cells or NK cells indicate the presence of the target T cell or NK cell.
[0247] Cells that are infected by a pathogen can present on their surface a polypeptide derived from the pathogen in the context of an MHC. This polypeptide / MHC can in turn be recognized by a T cell specific for the presented antigenic peptide. The T cell may then induce killing of the infected cell. Accordingly, provided herein are methods of expanding T cells 53185193632.1targeting pathogen-infected cells using protein complexes presenting on their surface a polypeptide derived from the pathogen. The T cells of interest are capable of both recognizing (1) the polypeptide derived from the pathogen, as presented on the infected cell (as part of an MHC) and (2) the epitope presented on the protein complex (as part of the particle’s MHC). In one embodiment, the polypeptide derived from the pathogen and the epitope are identical. In another embodiment, the polypeptide derived from the pathogen and the epitope differ from each other (but are still both recognized by the TCR on the T cells of interest). For example, the polypeptide derived from the pathogen could be longer or shorter than the epitope displayed by the MHC on the protein complex.
[0248] Similarly, cancer cells can present on their surface a cancer antigen in the context of an MHC. Any protein or polypeptide synthesized within the cancer cell can be the source of the antigenic peptide. Again, the cancer antigen / MHC can in turn be recognized by a T cell specific for the presented antigenic peptide. The T cell may then induce killing of the cancer cell. The T cells of interest are capable of both recognizing (1) the cancer antigen, as presented on the cancer cell (as part of an MHC) and (2) the epitope presented on the protein complex (as part of the particle’s MHC). In one embodiment, the cancer antigen and the epitope are identical. In another embodiment, the cancer antigen and the epitope differ from each other (but are still both recognized by the TCR on the T cells of interest). For example, the cancer antigen could be longer or shorter than the epitope displayed by the MHC on the protein complex.
[0249] Provided herein is a method of inducing killing of a cell infected by a pathogen, wherein the cell displays on its surface a polypeptide derived from the pathogen, the method comprising: (a) contacting a population of T cells with a protein complex disclosed herein, thereby generating a population of activated T cells, wherein each T cell comprises a TCR, wherein the TCR is capable of binding to the polypeptide derived from the pathogen and to the epitope presented by the protein complex; and (b) exposing the cell infected by the pathogen to the population of activated T cells. The epitope can be, for example, any epitope disclosed herein. In some embodiments, the pathogen is derived from a virus, bacterium, fungus, protozoon, parasite, helminth, or ectoparasite. In some embodiments, the viral pathogen is a CMV, HIV, or a hepatitis virus. In embodiments, the population of activated T cells is further expanded before step (b).54185193632.1
[0250] Provided is a method of killing a cancer cell, wherein the cell displays on its surface a cancer antigen, the method comprising: (a) contacting a population of T cells with a protein complex disclosed herein, thereby generating a population of activated T cells, wherein each T cell comprises a TCR, wherein the TCR is capable of binding to the cancer antigen and to the epitope presented by the protein complex; and (b) exposing the cancer cell to the population of activated T cells.
[0251] Anti-tumor responses of T cells contacted with the protein complexes described herein may be determined in xenograft tumor models. Tumors may be established using any human cancer cell line expressing the tumor-associated antigen presented by the protein complexes. The endpoint of the xenograft tumor models can be determined based on the size of the tumors, weight of animals, survival time, and histochemical and histopathological examination of the cancer, using methods known to one skilled in the art.
[0252] Methods of Treatment
[0253] Provided herein are methods of treating a disease in a subject in need thereof, the methods comprising administering to the subject a composition disclosed herein or a pharmaceutical composition comprising a composition disclosed herein.
[0254] As used herein, the terms “subject” and “patient” are used interchangeably, irrespective of whether the subject has undergone treatment in the past or is currently undergoing any form of treatment. As used herein, the terms “subject” and “subjects” may refer to any vertebrate, including, but not limited to, a mammal (e.g.. cow, pig. camel, llama, horse, goat, rabbit, sheep, hamsters, guinea pig, cat, dog, rat, and mouse), a non-human primate (for example, a monkey, such as a cynomolgus monkey, chimpanzee, etc.), and a human). The subject may be a human or a non-human. In some embodiments, the subject is a human. In some embodiments, the subject is immune-depleted.
[0255] The terms “treat,” “treated,” “treating,” or “treatment” as used herein refer to therapeutic treatment, wherein the object is to slow down (lessen) an undesired physiological condition, disorder, or disease, or to obtain beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to. alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (z.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or 55185193632.1improvement of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. The terms “prevent”, “prevention”, and the like refer to acting prior to overt disease or disorder onset, to prevent the disease or disorder from developing or to minimize the extent of the disease or disorder or slow its course of development.
[0256] Where a protein complex comprises a co-modulatory domain that is an activating polypeptide, contacting the T cell with the protein complex activates the epitope-specific T cell. Such methods can be useful for treating infections with a pathogen or for treating cancer.
[0257] Where a protein complex comprises a co-modulatory domain that is an inhibiting polypeptide, contacting the T cell with the protein complex inhibits the epitope-specific T cell. Such methods can be useful for treating autoimmune diseases, including, but not limited to rheumatoid arthritis, multiple sclerosis, and type 1 diabetes, during rejection of an organ transplant, Graft-versus-Host Disease, and certain inflammatory conditions such as diseases like inflammatory bowel disease (IBD) and psoriasis, and other diseases that involve chronic inflammation.
[0258] Provided is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a protein complex disclosed herein, wherein the subject has a cancer cell that displays on its surface a cancer antigen; and the subj ect has a T cell that comprises a TCR, wherein the TCR is capable of binding to the cancer antigen and to the epitope presented by the protein complex. As discussed herein, the T cells of interest are capable of both recognizing (1) the cancer antigen, as displayed on the cancer cell (as part of an MHC) and (2) the epitope presented on the protein complex (as part of the particle’s MHC). The protein complex may comprise one or more co-modulatory domains that promote T cell activation.
[0259] The epitope may be a cancer / tumor epitope disclosed herein.
[0260] The term “cancer” refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. Included in this definition are benign and malignant cancers, as well as dormant tumors, metastases, or micrometastases. Accordingly, the term “cancer” as used herein refers to an uncontrolled growth of cells, which interferes with the normal functioning of the bodily organs and systems, including cancer stem cells and tumor vascular niches. A subject that has a cancer is a subject having objectively 56185193632.1measurable cancer cells present in the subject's body. Included in this definition are benign and malignant cancers, as well as dormant tumors or micrometastases. Cancers that migrate from their original location and seed vital organs can eventually lead to the death of the subject through the functional deterioration of the affected organs. Hematopoietic cancers, such as leukemia, can out-compete the normal hematopoietic compartments in a subject, thereby leading to hematopoietic failure (in the form of anemia, thrombocytopenia, and neutropenia) ultimately causing death.
[0261] The compositions (including pharmaceutical compositions) disclosed herein may be administered in therapeutically effective amounts. An “effective amount” or “therapeutically effective amount” refers to an amount of the compound or agent that is capable of producing a medically desirable result in a treated subject. The treatment method can be performed in vivo or ex vivo, alone or in conjunction with other drugs or therapy. A therapeutically effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.
[0262] Cancers that can be treated by the compositions and methods disclosed herein include tumors that are not vascularized or are not substantially vascularized, as well as vascularized tumors. Cancers may comprise non-solid tumors (such as hematologic tumors, e.g., leukemias and lymphomas) or may comprise solid tumors. The ty pes of cancers to be treated with the compositions disclosed herein include, but are not limited to, carcinoma, blastoma and sarcoma, and certain leukemias or malignant lymphoid tumors, benign and malignant tumors and malignancies, e.g., sarcomas, carcinomas, and melanomas. Also included are adult tumors / cancers and pediatric tumors / cancers.
[0263] Hematologic cancers are cancers of the blood or bone marrow. Examples of hematologic (or haematogenous) cancers include leukemias, including acute leukemias (such as acute lymphocytic leukemia, acute myelocytic leukemia, acute myelogenous leukemia, promyelocytic, myelomonocytic, monocytic, and ery throleukemia), chronic leukemias (such as chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin’s lymphoma (indolent and high-grade forms), myeloma. Multiple myeloma, Waldenstrom's macroglobulinemia, heavy' chain disease, myelodysplastic syndrome, hairy' cell leukemia, and myelodysplasia.57185193632.1
[0264] Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors can be benign or malignant. The different types of solid tumors are named for the type of cells that form them (such as sarcomas, carcinomas, and lymphomas). Examples of solid tumors, such as sarcomas and carcinomas, include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and other sarcomas, synovium, mesothelioma, Ewing tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, carcinoma of the sweat gland, medullary thyroid carcinoma, papillary thyroid carcinoma, sebaceous gland carcinoma of pheochromocytomas, carcinoma papillary, papillary' adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms tumor, cervical cancer, testicular tumor, seminoma, bladder carcinoma, melanoma, and CNS tumors (such as glioma) (such as brainstem glioma and mixed gliomas), glioblastoma (also astrocytoma, CNS lymphoma, germinoma, medulloblastoma, Schwannoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, and brain metastasis).
[0265] Also provided herein are methods of reducing the growth of a tumor, reducing cancer sternness, reducing tumor-associated fibrosis, reducing tumor metastasis, increasing cytokine production in the tumor microenvironment, increasing anti-tumor immunity, increasing infiltration of a tumor with immune cells, or reducing T cell tolerance, the methods comprising administering to the subject a protein complex disclosed herein.
[0266] The compositions disclosed herein (e.g., the protein complexes, cells, and pharmaceutical compositions disclosed herein) can be administered in a manner appropriate to the disease to be treated (or prevented). The amount and frequency of administration will be determined by factors such as the condition of the patient, and the t pe and severity of the patient's disease, although appropriate dosages can be determined by clinical trials. The precise amount of the compositions disclosed herein to be administered can be determined by a physician having accounted for individual differences in age, weight, tumor size, extent of infection or metastasis, and the patient’s condition (subject).
[0267] The compositions can also be administered several times at these dosages. Cells disclosed herein can be administered using infusion techniques that are commonly known in 58185193632.1immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988). The optimal dose and treatment regimen for a particular patient can be determined by one skilled in the art of medicine by monitoring the patient for signs of the disease and adjusting the treatment accordingly.
[0268] The administration of the present compositions can be carried out in any convenient way, including infusion or injection (e.g., intravenous, intrathecal, intramuscular, intraluminal, intratracheal, intraperitoneal, or subcutaneous), or other methods known in the art. Administration can be once every four weeks, once every three weeks, every two weeks, once a week, or more often, but the frequency may be decreased during a maintenance phase of the disease or disorder. In some embodiments, the composition is administered by intravenous infusion.
[0269] In certain cases, the compositions described herein are administered to a patient together with (e.g., before, simultaneously, or consecutively) any number of relevant treatment modalities, including any of the protein complexes as described herein. Also described herein, the compositions disclosed herein can be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablating agents such as CAMPATH, anti-cancer antibodies, CD3 or other antibody therapies, cytoxine, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids. FR901228, cytokines, and irradiation.
[0270] The protein complexes described herein may be used for treating or preventing an infection. The infections include, without limitation, infections caused by viruses, bacteria, fungi, protozoa, parasites, helminths, and ectoparasites. The infectious agent can be, without limitation, a virus, a bacterium, a fungus, a protozoon, a parasite, a helminth, and an ectoparasite. In some embodiments, the infectious agent is a CMV, HIV, or a hepatitis virus.
[0271] Provided herein is a method of treating an infection with a pathogen in a subject in need thereof, the method comprising administering to the subject a protein complex disclosed herein, wherein the subject has a cell that displays on its surface a polypeptide derived from the pathogen; and the subject has a T cell that comprises a TCR, wherein the TCR is capable of binding to the polypeptide derived from the pathogen and to the epitope presented by the protein complex. The protein complex may comprise one or more co-modulatory domains that promote T cell activation.59185193632.1
[0272] In some embodiments, the pathogen is a bacterial, viral, or fungal pathogen. In one embodiment, the pathogen is a viral pathogen.
[0273] Provided herein are methods of treating an autoimmune disease, rejection of an organ transplant, Graft-versus-Host Disease, or an inflammatory condition that involves chronic inflammation, the method comprising administering to the subject a protein complex disclosed herein, presenting an autoimmune peptide. The protein complex may comprise one or more co-modulatory domains that reduce or abolish T cell activation.
[0274] Combination Therapies
[0275] In some embodiments, the method may further include administering to the subject a second therapeutic agent. In some embodiments, the composition is administered to the subject before, after, or concurrently with the second therapeutic agent.
[0276] ‘’Combination’’ therapy, as used herein, unless otherwise clear from the context, is meant to encompass administration of two or more therapeutic agents in a coordinated fashion, and includes, but is not limited to, concurrent dosing. Specifically, combination therapy encompasses both co-administration (e.g, administration of a co-formulation or simultaneous administration of separate therapeutic compositions) and serial or sequential administration, provided that administration of one therapeutic agent is conditioned in some way on administration of another therapeutic agent. For example, one therapeutic agent may be administered only after a different therapeutic agent has been administered and allowed to act for a prescribed period of time. See, e.g., Kohrt et al. (2011) Blood 117:2423.
[0277] In one embodiment, 2, 3, 4, 5, 6, 7, 8, 9, or 10 different protein complexes disclosed herein are administered to the patient, consecutively or concurrently.
[0278] In some embodiments, the second therapeutic agent is an anti-cancer or anti-tumor agent.
[0279] In some embodiments, the method further comprises administering a therapeutically effective amount of an immune checkpoint modulator. Checkpoint proteins interact with specific ligands that send a signal into the T cell and switch off or inhibit T cell function. By expressing high levels of checkpoint proteins on their surface, cancer cells can control the function of T cells that enter the tumor microenvironment, thus suppressing the anticancer immune response. Examples of immune checkpoint modulators include PD1, PDL1, CTLA4, TIM3, LAG3, and TRAIL. The immune checkpoint protein Programmed Death-1 (PD-1) is a key immune checkpoint receptor expressed by activated T and B cells and mediates 60185193632.1immunosuppression. PD-1 is a member of the CD28 family of receptors, which includes CD28, CTLA-4. ICOS, PD-1. and BTLA. Two cell surface glycoprotein ligands for PD-1 have been identified. Programmed Death Ligand- 1 (PD-L1) and Programmed Death Ligand-2 (PD-L2), that are expressed on antigen-presenting cells as well as many human cancers and have been shown to downregulate T cell activation and cytokine secretion upon binding to PD-1 (Freeman et al., 2000; Latchman et al., 2001). Inhibition of the PD-1 / PD-L1 interaction can promote potent antitumor activity. Examples of PD-1 inhibitors include, but are not limited to, Pembrolizumab (MK-3475), Nivolumab (MDX-1106), Cemiplimab-rwlc (REGN2810), Pidilizumab (CT-011), Spartalizumab (PDR001), Tislelizumab (BGB-A317), PF-06801591, AK105, BCD-100, BI 754091, JS001, LZM009, MEDI0680, MGA012, Sym021, TSR-042. Examples of PD-L1 inhibitors include, but are not limited to, Atezolizumab (MPDL3280A), Durvalumab (MEDI4736), Avelumab (MSB0010718C), BGB-A333, CK-301, CS1001, FAZ053, KN035, MDX-1105, MSB2311, SHR-1316. The checkpoint modulators may be administered simultaneously, separately, or concurrently with the compositions disclosed herein.
[0280] In some embodiments, the method further comprises administering a therapeutically effective amount of a ‘'chemotherapeutic agent,” which is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, methyldopa, and uredopa; ethylenimines and methylamel amines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; cally statin; CC-1065 (including its adozelesin, carzelesin, and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin: spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine. chlorophosphamide. estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e g. calicheamicin); dynemicin, including dynemicin A; an esperamicin;61185193632.1as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotics chromophores), aclacinomysins. actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholinodoxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tuberci din, ubenimex, zinostatin, zorubicin; anti -metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine. azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; antiadrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK; razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2 ’.2”-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C"’); cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (TAXOL, Bristol-Myers Squibb Oncology, Princeton, N. J.) and doxetaxel (TAXOTERE, Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti -estrogens including for example tamoxifen,62185193632.1raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone. and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, xeloda, gemcitabine, KRAS mutation covalent inhibitors and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Additional examples include irinotecan, oxaliplatinum, and other standard colon cancer regimens.
[0281] For treatment of infections, combination therapy described herein can encompass co-administering compositions and methods described herein with an antibiotic, an anti-fungal drug, an anti-viral drug, an anti-parasitic drug, an anti-protozoal drug, or a combination thereof.
[0282] Non-limiting examples of useful antibiotics include lincosamides (clindamycin); chloramphenicols; tetracyclines (such as Tetracycline, Chlortetracycline, Demeclocy cline, Methacycline, Doxycycline, Minocycline); aminoglycosides (such as Gentamicin, Tobramycin, Netilmicin, Amikacin, Kanamycin, Streptomycin, Neomycin); beta-lactams (such as penicillins, cephalosporins, Imipenem, Aztreonam); vancomycins; bacitracins; macrolides (erythromycins), amphotericins; sulfonamides (such as Sulfanilamide, Sulfamethoxazole, Sulfacetamide, Sulfadiazine, Sulfisoxazole, Sulfacytine, Sulfadoxine, Mafenide, p-Aminobenzoic Acid, Trimethoprim-Sulfamethoxazole); Methenamine; Nitrofurantoin; Phenazopyridine; trimethoprim; rifampicins; metronidazoles; cefazolins; Lincomycin; Spectinomycin; mupirocins; quinolones (such as Nalidixic Acid, Cinoxacin, Norfloxacin, Ciprofloxacin. Perfloxacin. Ofloxacin. Enoxacin. Fleroxacin, Levofloxacin); novobiocins; polymixins; gramicidins; and antipseudomonals (such as Carbenicillin, Carbenicillin Indanyl, Ticarcillin, Azlocillin, Mezlocillin, Piperacillin) or any salts or variants thereof. The antibiotic used will depend on the type of bacterial infection.
[0283] Non-limiting examples of useful anti-fungal agents include imidazoles (such as griseofulvin, miconazole, terbinafine, fluconazole, ketoconazole, voriconazole, and itraconazole); polyenes (such as amphotericin B and nystatin); Flucytosines; and candicidin or any salts or variants thereof.
[0284] Non-limiting examples of useful anti-viral drugs include interferon alpha, beta or gamma, didanosine, lamivudine, zanamivir, lopinavir, nelfinavir, efavirenz, indinavir, valacyclovir, zidovudine, amantadine, rimantidine, ribavirin, ganciclovir, foscamet, and acyclovir or any salts or variants thereof.63185193632.1
[0285] Non-limiting examples of useful anti-parasitic agents include chloroquine, mefloquine, quinine, primaquine, atovaquone, sulfasoxine, and pyrimethamine or any salts or variants thereof.
[0286] Non-limiting examples of useful anti-protozoal drugs include metronidazole, diloxanide, iodoquinol, trimethoprim, sulfamethoxazole, pentamidine, clindamycin, primaquine, pyrimethamine, and sulfadiazine or any salts or variants thereof.
[0287] In some embodiments, the protein complexes disclosed herein are co-admimstered with one or more cytokines. This can serve to enhance the selective differentiation and / or expansion of desired T cells.
[0288] Kits
[0289] Further embodiments disclosed herein can concern kits for use with methods and compositions. Kits can also include a suitable container, for example, vials, tubes, mini- or microfuge tubes, test tubes, flasks, bottles, syringes or other containers. Where an additional component or agent is provided, the kit can contain one or more additional containers into which this agent or component may be placed. Kits herein will also typically include a means for containing the protein complex or MHC scaffold and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained. Optionally, one or more additional active agents such as, e.g., anti-inflammatory agents, anti-viral agents, anti-fungal or antibacterial agents or anti-tumor agents may be needed for compositions described.
[0290] It is to be understood that this disclosure is not limited to the particular molecules, compositions, methodologies, or protocols described, as these may vary. Any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments disclosed herein. It is further to be understood that this disclosure includes all possible combinations of such particular features. For example, where a particular feature is disclosed in the context of a particular aspect or embodiment of the disclosure, or a particular claim, that feature can also be used, to the extent possible, in combination with and / or in the context of other particular aspects and embodiments disclosed herein.
[0291] Where reference is made herein to a method comprising two or more defined steps, the defined steps can be carried out in any order or simultaneously (except where the context excludes that possibility), and the method can include one or more other steps which are carried 64185193632.1out before any of the defined steps, between two of the defined steps, or after all the defined steps (except where the context excludes those possibilities).
[0292] All other referenced patents and applications, scientific articles, book chapters, etc. are incorporated herein by reference in their entireties. Furthermore, where a definition or use of a term in a reference, which is incorporated by reference herein is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0293] To facilitate a better understanding of the present disclosure, the following examples of specific embodiments are given. The following examples should not be read to limit or define the entire scope of the disclosure.EXAMPLES
[0294] Example 1: Design of a protein complex comprising an MHC class I polypeptide and an oxime-coupled antigenic peptide (epitope)
[0295] As discussed herein, in physiological contexts, an MHC class I molecule generally comprises a glycoprotein heavy chain, also referred to as the alpha chain, which has three extracellular domains (e.g, alphal. alpha2 and alpha3). The heavy chain is noncovalently associated with a soluble extracellular subunit beta2m.
[0296] A protein complex was designed comprising an MHC class I complex comprising an alpha chain and a beta2m, wherein the alpha chain and the beta2m are covalently linked. The alpha chain and the beta2m may be covalently linked between domain alpha3 of the alpha chain and the beta2m. The alpha chain and the beta2m may be covalently linked with a disulfide bond. See Fig. 1 (panel 2) for an illustration. See Table 3 for illustrative, non-limiting mutations (e.g., R12C in beta2m and A236C in HLA-A*02:01 MHC).
[0297] The heavy chain of the MHC may further comprise an additional, engineered disulfide that stabilizes the MHC in the absence of peptide and enhances recombinant expression. See Table 3 for illustrative, non-limiting mutations (e.g., Y84C / A139C in HLA-A*02:01 MHC).
[0298] An antigenic peptide is covalently bound to the MHC via an oxime linkage. The antigenic peptide may be covalently bound to the MHC complex via a linker. The N-terminus of the beta2m in the MHC complex may contain, for example, a serine or threonine residue65185193632.1that allows covalent linkage of the beta2m to the antigenic peptide using the oxime coupling methods described herein. See Fig. 1 (panel 1), Fig.5 and Fig. 6 for illustration.
[0299] The protein complex may further comprise a co-modulatory domain, including, but not limited, to a stimulatory domain, an inhibitory domain, a targeting / affinity domain, or additional functional domains. See Fig. 1 (panel 3) for an illustration. Different protein complex designs are contemplated herein. See Fig. 3 for illustrations. Constructs without a co-modulatory domain are also referred to as ’MODLESS” herein.
[0300] The protein complex or MHC scaffold may also comprise an Fc region comprising, e.g., a CH2 and / or a CH3 domain, to support oligomerization, enhance avidity, and allow for easier purification. See Fig. 1 (panel 4) for an illustration.
[0301] Also designed were empty MHC scaffolds (Fig. 2, right panel) that may be loaded with an antigenic peptide to create an epitope-loaded protein complex (Fig. 2, left panel). See Table 2 and Table 3 for illustrative sequences.Table 2. Illustrative designs of protein complexes. IL-15-sushi / IL15 fusion is an IL- 15 agonist comprising IL-15 and the sushi domain (high-affinity IL-15 binding domain) of human IL-15Ralpha).185193632.1Table 3. Illustrative designs of protein complexes. The optional TEV cleavage site may, for example, be useful for SDS-PAGE gel shift analysis.67185193632.168 185193632.169 185193632.170 185193632.171 185193632.172 185193632.1185193632.174 185193632.1
[0302] Example 2: Loading of MHC scaffolds with antigenic peptides using oxime coupling to produce protein complexes
[0303] A strategy was designed that allows for the highly efficient and rapid chemical coupling of synthetic peptides to the N-terminus of beta2m in the context of an empty MHC molecule (also referred to as an MHC scaffold). Specifically, aldehyde-alkoxy amine chemistry (also referred to herein as oxime coupling) is a versatile bio-orthogonal conjugation strategy that benefits from high chemo-selectivity and regio-selectivity, mild reaction conditions, and hydrolytic stability of the resultant oxime bond.
[0304] For the reaction to occur, an N-terminal serine or threonine (z.e., an alpha-amino alcohol) on beta2m is subjected to periodate (NaIO₄-mediated oxidation. This reaction yields an N-terminal aldehyde on beta2m suitable for bio-orthogonal coupling. Conjugation was performed using aniline or phenylenediamine derivatives as catalysts, allowing for the covalent 75185193632.1linkage of a nucleophilic alkoxyamine-bearing peptide (Fig. 4) to the empty MHC scaffold (Fig. 5). Numerous peptide structures for placement of the alkoxy amine on the peptide were evaluated, with the following two showing the best coupling: C-terminal aminooxy-PEG2-amine (Fig. 4, top panel) and aminooxyacetic acid placed on the side chain of a C-terminal lysine residue (Fig. 4, bottom panel).
[0305] Notably, this strategy is applicable to any synthetic peptide and any MHC allele.
[0306] Example 3: Oxime coupling allows for the near-quantitative coupling of a wide range of synthetic peptides
[0307] The NaIO₄-mediated oxidation and subsequent conjugation steps took only 10 minutes each. Reaction progress could be monitored using a gel shift assay. This assay reports on the clear reduction in SDS-PAGE mobility of beta2m when the antigenic peptide (or other ligands) is conjugated to beta2m.
[0308] As illustrated with a protein complex without a co-modulatory domain (“MODLESS 1ST"), the current protocol allows for near-quantitative (z. e., near-complete) coupling of a wide range of synthetic peptides, including phosphorylated peptides (Fig. 6).
[0309] See Table 4 for illustrative peptide sequences.Table 4. Illustrative peptides. CMV = Cytomegalovirus. HIV = Human Immunodeficiency Vims. T1D = Type 1 Diabetes. IGRP = Islet-specific glucose-6-phosphatase catalytic subunit-related protein. IRS2 = Insulin Receptor 2,76185193632.177 185193632.1
[0310] In addition, the near-quantitative coupling of the IV9 subdominant antigen from HIV to an MHC scaffold was demonstrated (Fig.7). This peptide-bearing MHC complex could not be produced using standard recombinant expression technology.
[0311] Importantly, near-quantitative conjugation was also achieved with protein complexes bearing co-modulatory domains, such as IL-2, IL-15 / Ralpha, and CD28 agonist scFv (Fig.8).
[0312] Of note, the oxime linkage was stable during SDS-PAGE sample preparation (3 minutes boiling in SDS sample buffer) and subsequent denaturing electrophoresis.185193632.1
[0313] Example 4: Biochemical characterization of oxime-coupled protein complexes
[0314] The activity of the protein complexes loaded with antigenic peptides was assessed using different biochemical analyses.
[0315] It was shown that protein complexes generated using oxime coupling recognize cognate T cells (via TCR engagement) as effectively as T cell-modulating polypeptides generated using traditional recombinant approaches (Fig. 9).
[0316] Additionally, the impact of NaIO₄-mediated oxidation on the binding activity of several protein complexes with co-modulatory domains was evaluated by subjecting recombinant protein complexes bearing IL-2, IL-15 / Ralpha, or CD28 agonist scFv to the same procedure used to convert N-terminal Ser / Thr to an aldehyde functionality' for subsequent conjugation. HEK293 cells transfected with GFP and either IL-2Ralpha, beta, gamma (for IL-2), IL-15Ralpha, beta, gamma (for IL-15 / Ralpha), or CD28 (for CD28 agonist scFv) were challenged with the cell-modulating polypeptides with co-modulatory domains (i.e., recombinant MHC complexes bearing modulatory domains following oxidation). Binding was quantified by FACS.
[0317] NaIO₄-mediated oxidation had no appreciable impact on co-modulatory domain engagement of cognate receptors (Fig. 10A, Fig. 10B, and Fig. 10C).
[0318] Example 5: Functional characterization of oxime-coupled protein complexes
[0319] HLA-A*02:01+CMV+PBMCs were treated with increasing concentrations of CMV- or HIV -conjugated protein complexes (without co-modulatory domain) for 12-14 days. The population of CMV-specific CD8+T cells was quantified via flow cytometry. Recombinantly expressed CMV- or HIV -protein complexes (without co-modulatory domain) served as positive controls for comparison.
[0320] Delivery7of the primary TCR signal alone without an additional co-modulatory signal resulted in significant CMV-specific T cell expansion (Fig. 11). CMV-conjugated protein complexes (without co-modulatory domain) resulted in a 53-fold expansion at the highest protein complex concentration (100 nM). Similar expansion was observed in PBMCs from two additional donors. No CMV-specific expansion was observed when treated with the non-cognate HIV-conjugated complex.
[0321] As compared to untreated conditions, the highest concentration of CMV-conjugated and IL-2-bearing protein complexes (10 nM) markedly increased the fraction of CMV-specific 79185193632.1CD8+T cells from 1.5% of CD8+T cells to 55.7% (Fig. 12). Similar expansion was observed in PBMCs from a second donor.
[0322] These results show that CMV-conjugated protein complexes without a co-modulatory7domain, or with an IL-2 co-modulatory domain, respectively, elicited robust and selective expansion of CMV -targeting CD8+T cells that was comparable to that of the positive control recombinant counterparts.
[0323] Example 6: An alternative TEV cleavage strategy for generation of N-terminal serine residues
[0324] Introduction of a TEV cleavage site following in a recombinantly produced peptide / MHC fusion provides an alternative production strategy for the generation of N-terminal serine or threonine in an MHC scaffold (Fig. 13). The peptide previously located N-terminally of the TEV cleavage site was removed.
[0325] The TEV protease recognition sequence with the highest catalytic efficiency is ENLYFQAS (SEQ ID NO:77). with cleavage atA. However, the amino acid in the last position (instead of S) can also be G, A, M, C, or H.
[0326] Overnight treatment with TEV protease allowed for peptide cleavage and revealed an N-terminal serine residue for subsequent oxidation and coupling (Fig. 14).
[0327] Example 7: Protein complexes comprising MHC class I molecules other than HLA-A2-derived MHCs and cysteine-containing peptides
[0328] The compositions and methods disclosed herein can be used with any MHC class I allele-containing scaffold derived from, e.g., human, mouse, or another organism. For example, protein complexes may be based on HLA-C*03:04 and may comprise peptides containing a cysteine (Fig. 15).
[0329] Protein complexes disclosed herein may further comprise affinity' reagents, including, but not limited to, antibodies (e.g., based on IgG, IgA, IgM, scFv, nanobodies, etc.), naturally occurring or recombinant created ligands / binders or analogs thereof, and other affinity reagents. The protein complex may be conjugated to a small molecule.
[0330] The protein complexes disclosed herein may comprise one or more stimulatory, inhibitory, differentiation, or other co-modulatory domains. Examples of co-modulatory domains include, but are not limited to, CD28 agonist scFv, single chain 4-1BBL, IL- 80185193632.115 / Ralpha, IL-2, PD-L1, etc. The protein complexes can have more than one co-modulatory domain (eg., the protein complexes may be bispecific and trispecific engagers). Co-modulatory domains can be used in single chain and two chain complexes, see Table 2). Co-modulatory domains can be attached at multiple attachment sites, including at the C-terminus of the Fc segment, the N-terminus of the MHC heavy chain, and the C-terminus of the beta2m in the two chain MHC scaffold constructs.
[0331] Example 8: Phenotypic characterization of expanded CD8+T cells
[0332] HLA-A*02:01+CMV+PBMCs were treated with 10 nM CMV-conjugated IL-2 or MODLESS Immuno-STATs for 12-14 days and the population of CMV-specific CD8+T cells quantified via flow cytometry. Recombinantly expressed IL-2 or MODLESS CMV-IST served as a positive control for comparison. To assess the phenotype of the expanded CMV-tetramer+CD8+T cells, PBMCs were re-stimulated overnight with CMV- or HIV -pulsed T2 cells. Antibodies targeting the degranulation marker CD 107a and intracellular cytokines IFNgamma and TNFalpha were used to assess T cell functionality (Fig. 16).
[0333] Expanded CMV+CD8+T cells that were re-stimulated by a cognate target of interest (CMV-loaded T2 cells) contained a higher fraction of CD107a, IFNg, and TNFathan expanded CMV+CD8+T cells that were re-stimulated by a non-cognate target (HIV -loaded T2 cells). The data shows that CD8+T cells expanded by CMV-conjugated MODLESS and IL-2 bearing ISTs are polyfunctional and display antigen-selectivity.
[0334] Furthermore, cytolytic activity of expanded CMV+CD8+T cells against CMV or HIVloaded T2 cells as target cells was evaluated using an EuTDA cytotoxicity assay. CMV+T cells expanded by conjugated-ISTs displayed cytolytic activity directed at CMV-loaded T2 cells as compared to minimal cytolysis of HIV-loaded T2 cells (Fig. 17). The data shows that CMV-conjugated IL-2 or MODLESS Immuno-STAT treatment amplified the expression of cytotoxic markers and enhanced antigen-dependent cytotoxicity of cognate antigen-specific CD8+T cells.
[0335] Example 9: Alternative coupling methods
[0336] Additional nitrogen-containing nucleophiles were tested for covalent linkage of the peptide to the MHC, including hydrazino- and hydrazide-containing nucleophiles (Fig. 18).81185193632.1Successful conjugation of Alexa488-hydrazide to the N-terminus of beta2m was confirmed via SDS-PAGE and Stochastic Optical Reconstruction Microscopy (STORM) (Fig. 19).185193632.1
Claims
CLAIMSWe claim:
1. A protein complex comprising:(a) a major histocompatibility’ (MHC) complex comprising (i) a class I major histocompatibility (MHC) heavy chain or a fragment, variant, or derivative thereof, and (ii) a beta 2 microglobulin (beta2m) polypeptide or a fragment, variant, or derivative thereof; and(b) an epitope;wherein the epitope is coupled to the N-terminus of the beta2m polypeptide or the fragment, variant, or derivative thereof via an oxime or hydrazone linkage.
2. The protein complex of claim 1, wherein the protein complex further comprises a first linker between the epitope and the oxime or hydrazone linkage.
3. The protein complex of claim 2, wherein the first linker is a polypeptide linker or an amino acid polymer hybrid.
4. The protein complex of any one of claims 1-3, wherein the MHC heavy chain comprises a human class I MHC polypeptide derived from HLA-A. HLA-B, HLA-C, HLA-E. HLA-F, or HLA-G.
5. The protein complex of claim 4, wherein the MHC heavy chain comprises a human class I MHC polypeptide derived from an HLA-A, HLA-B, HLA-C. HLA-D, HLA-E, HLA-F, or HLA-G allele.
6. The protein complex of claim 5, wherein the MHC heavy chain comprises a human class I MHC polypeptide derived from HLA-A*02: 01 or HLA-C*03:04.
7. The protein complex of any one of claims 1-3, wherein the MHC heavy chain comprises a murine class I MHC polypeptide derived from H-2K, H-2D, H-2L, H-2Q, H-2M or H-2T.83185193632.
18. The protein complex of any one of claims 1-3, wherein the MHC heavy chain comprises a simian class I MHC polypeptide derived from a A, B, or C, E, F, or G gene.
9. The protein complex of any one of claims 1-3, wherein the MHC heavy chain comprises a canine class I MHC poly peptide derived from DLA-I.
10. The protein complex of any one of claims 1-3, wherein the MHC heavy chain comprises a sequence that is at least 80% identical to any one of SEQ ID NOs: 16-18.
11. The protein complex of claim 10. wherein the MHC heavy chain comprises any one of SEQ ID NOs: 16-18.
12. The protein complex of any one of claims 1-11, wherein the beta2m polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO:21 or SEQ ID NO:22.
13. The protein complex of any one of claims 1-11, wherein the beta2m polypeptide comprises SEQ ID NO:21 or SEQ ID NO:22.
14. The protein complex of any one of claims 1-13, wherein the MHC heavy chain or the fragment, variant, or derivative thereof comprises an internal disulfide bond.
15. The protein complex of claim 14, wherein the MHC heavy chain or the fragment, variant, or derivative thereof comprises an internal disulfide bond that comprises a disulfide bond between residues 84C and 139C, numbered relative to any one of SEQ ID NOs: 16-18.
16. The protein complex of any one of claims 1-15, wherein the MHC heavy chain or the fragment, variant, or derivative thereof is connected to the beta2m polypeptide or the fragment, variant, or derivative thereof via a disulfide bond.
17. The protein complex of claim 16, wherein the MHC heavy chain or the fragment, variant, or derivative thereof comprises an alphal, alpha2, and alpha3 chain, and wherein the alpha384185193632.1chain and the beta2m polypeptide or the fragment, variant, or derivative thereof are connected via the disulfide bond.
18. The protein complex of claim 17, wherein the disulfide bond connecting the alpha3 chain and the beta2m polypeptide or the fragment, variant, or derivative thereof is between residue 236C of the MHC heavy chain or the fragment, variant, or derivative thereof (numbered relative to SEQ ID NO: 16 or SEQ ID NO: 18) and residue 12C of the beta2m polypeptide or the fragment, variant, or derivative thereof (numbered relative to SEQ ID NO:21).
19. The protein complex of any one of claims 1-18, wherein the protein complex further comprises a second linker between the N-terminal amino acid of the beta2m polypeptide or the fragment, variant, or derivative thereof and the remainder of the beta2m polypeptide or the fragment, variant, or derivative thereof.
20. The protein complex of claim 19, wherein the second linker is a polypeptide linker.
21. The protein complex of any one of claims 1-20, wherein the protein complex further comprises a fragment crystallizablc (Fc) domain.
22. The protein complex of claim 21, wherein the N-terminus of the Fc domain is connected to the C-terminus of the MHC heavy chain or the fragment, variant, or derivative thereof via a third linker.
23. The protein complex of claim 22, wherein the third linker is a polypeptide linker.
24. The protein complex of any one of claims 1-23, wherein the protein complex further comprises one or more co-modulatory domains.
25. The protein complex of claim 24, wherein the one or more co-modulatory domains are selected from the group consisting of a CD28 agonist, IL-15, or IL-2.85185193632.
126. The protein complex of claim 24, wherein at least one of the one or more co-modulatory domains comprises a sequence that is at least 80% identical to any one of SEQ ID NOs:23-27.
27. The protein complex of claim 26, wherein at least one of the one or more co-modulatory domains comprises any one of SEQ ID NOs:23-27.
28. The protein complex of any one of claims 24-27, wherein the protein complex comprises at least two co-modulatory domains and wherein the two co-modulatory domains are connected to each other via a fourth linker.
29. The protein complex of claim 28, wherein the fourth linker is a polypeptide linker.
30. The protein complex of any one of claims 24-29, wherein the one or more co-modulatory domains are connected to (1) the C-terminus of the beta2m polypeptide or the fragment, variant, or derivative thereof or (2) the N-terminus of the MHC heavy chain or the fragment, variant, or derivative thereof via a fifth linker.
31. The protein complex of claim 30, wherein the fifth linker is a polypeptide linker.
32. The protein complex of any one of claims 1-29, wherein the MHC heavy chain or the fragment, variant, or derivative thereof and the beta2m polypeptide or the fragment, variant, or derivative thereof are part of a continuous amino acid chain.
33. The protein complex of claim 32, wherein the MHC heavy chain or the fragment, variant, or derivative thereof, and the beta2m polypeptide or the fragment, variant, or derivative thereof are connected through a sixth linker.
34. The protein complex of claim 33, wherein the sixth linker is a polypeptide linker.
35. The protein complex of any one of claims 32-34, wherein the protein complex comprises one or more co-modulatory domains, wherein the protein complex comprises an Fc domain,86185193632.1and wherein the one or more co-modulatory domains are connected to the C-terminus of the Fc domain.
36. The protein complex of any one of claims 3, 20, 23, 28, 31, or 34, wherein the polypeptide linker predominantly comprises glycines, serines, and / or alanines.
37. The protein complex of claim 36. wherein the polypeptide linker comprises any one of SEQ ID NOs:28-37.
38. The protein complex of any one of claims 1-37, wherein the epitope is 5 to 20 amino acids long.
39. The protein complex of any one of claims 1-38, wherein the epitope is derived from polypeptide from a bacterial, viral, fungal, protozoan, or multicellular organism.
40. The protein complex of claim 39, wherein the epitope is derived from a cytomegalovirus (CMV) polypeptide, a human immunodeficiency virus (HIV) polypeptide, a SARS-CoV-2 virus polypeptide, or a hepatitis virus polypeptide.
41. The protein complex of claim 39, wherein the epitope comprises a sequence derived from CMV pp65, HIV gag, HIV reverse transcriptase, or SARS-CoV-2 spike protein.
42. The protein complex of claim 39, wherein the epitope comprises any one of SEQ ID NO:39, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO 55, SEQ ID NO:60, or SEQ ID NO:61.
43. The protein complex of any one of claims 1-38, wherein the epitope is a cancer antigen or fragment thereof.
44. The protein complex of claim 43, wherein the cancer antigen is melanoma antigen recognized by T cells 1 (MART-1).87185193632.
145. The protein complex of any one of claims 24 or 28-38, wherein the epitope is an autoimmune epitope or fragment thereof.
46. The protein complex of any one of claims 45, wherein the autoimmune epitope is preproinsulin, or islet-specific glucose-6-phosphatase catalytic subunit-related protein (I GRP).
47. A pharmaceutical composition comprising (a) the protein complex of any one of claims 1-46 and (b) a pharmaceutically acceptable excipient.
48. A method of activating a T cell comprising a TCR, the method comprising contacting the T cell with:(a) the protein complex of any one of claims 1-46; or(b) a pharmaceutical composition comprising the protein complex of any one of claims 1-46 and a pharmaceutically acceptable excipient;wherein the TCR of the T cell binds to the epitope.
49. A method of inducing expression of pro-inflammatory cytokines in a T cell comprising a TCR, the method comprising contacting the T cell with:(a) the protein complex of any one of claims 1-46; or(b) a pharmaceutical composition comprising the protein complex of any one of claims 1-46 and a pharmaceutically acceptable excipient;wherein the TCR of the T cell binds to the epitope.
50. A method of expanding a population of T cells or NK cells each comprising a TCR, the method comprising contacting the population of T cells with:(a) the protein complex of any one of claims 1-46; or(b) a pharmaceutical composition comprising the protein complex of any one of claims 1-46 and a pharmaceutically acceptable excipient;wherein the TCR of the T cells binds to the epitope.
51. A method of inducing killing of a cell infected by a pathogen, wherein the cell displays on its surface a polypeptide derived from the pathogen, the method comprising:88185193632.1(a) contacting a population of T cells with the protein complex of any one of claims 39-42 or with a pharmaceutical composition comprising the protein complex of any one of claims 39-42 and a pharmaceutically acceptable excipient, thereby generating a population of activated T cells, wherein each T cell comprises a TCR, wherein the TCR is capable of binding to the polypeptide derived from the pathogen and to the epitope; and(b) exposing the cell infected by the pathogen to the population of activated T cells.
52. A method of inducing killing of a cancer cell, wherein the cancer cell displays on its surface a cancer antigen, the method comprising:(a) contacting a population of T cells with the protein complex of claim 43 or 44 or with a pharmaceutical composition comprising the protein complex of claim 43 or 44 and a pharmaceutically acceptable excipient, thereby generating a population of activated T cells, wherein each T cell comprises a TCR, wherein the TCR is capable of binding to the cancer antigen and to the epitope; and(b) exposing the cancer cell to the population of activated T cells.
53. The method of claims 51 or 52, wherein the population of activated T cells is further expanded before step (b).
54. A method of treating an infection with a pathogen in a subject in need thereof, the method comprising administering to the subject the protein complex of any one of claims 39-42 or a pharmaceutical composition comprising the protein complex of any one of claims 39-42 and a pharmaceutically acceptable excipient, wherein:the subject has a cell that displays on its surface a polypeptide derived from the pathogen; andthe subject has a T cell that comprises a TCR, wherein the TCR is capable of binding to the polypeptide derived from the pathogen and to the epitope.
55. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the protein complex of claim 43 or 44 or a pharmaceutical89185193632.1composition comprising the protein complex of claim 43 or 44 and a pharmaceutically acceptable excipient, wherein:the subject has a cancer cell that displays on its surface a cancer antigen; and the subject has a T cell that comprises a TCR, wherein the TCR is capable of binding to the cancer antigen and to the epitope.
56. A method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject the protein complex of claim 45 or 46 or a pharmaceutical composition comprising the protein complex of claim 45 or 46 and a pharmaceutically acceptable excipient, wherein the subject has a T cell that comprises a TCR, wherein the TCR is capable of binding to the autoimmune epitope and to the epitope, and wherein the one or more co-modulatory domains are inhibiting co-modulatory domains.
57. The method of any one of claims 54-56, wherein the subject is a mammal, preferentially a human.
58. A method of making a protein complex comprising (a) an MHC complex comprising (i) a class I MHC heavy chain or a fragment, variant, or derivative thereof, and (ii) a beta2m polypeptide or a fragment, variant, or derivative thereof and (b) an epitope, the method comprising:(a) oxidizing the N-terminal amino acid of the beta2m polypeptide or the fragment, variant, or derivative thereof, to form an aldehyde at the N-terminal position of the beta2m polypeptide or the fragment, variant, or derivative thereof, wherein the N-terminal amino acid is serine or threonine;(b) reacting the aldehyde formed in step (a) with a primary amine catalyst to form a Schiff base; and(c) reacting the Schiff base formed in step (b) with an epitope comprising a functional group comprising an alkoxy amine, a hydrazino, or a hydrazide to form the protein complex, wherein in the protein complex, the epitope is coupled to the N-terminus of the beta2m polypeptide or the fragment, variant, or derivative thereof via an oxime or a hydrazone linkage.90185193632.
159. The method of claim 58, wherein the functional group comprising an alkoxyamine is selected from the group consisting of:
60. The method of claim 58, wherein the functional group comprising a hydrazino or hydrazide is selected from the group consisting of61. The method of any one of claims 58-60, wherein the protein complex further comprises a seventh linker between the epitope and the functional group.
62. The method of claim 61, wherein the seventh linker is a polypeptide linker or a polyethylene glycol linker.
63. The method of any one of claims 58-62, wherein in step (a) the N-terminal amino acid on the beta2m polypeptide or fragment, variant, or derivative thereof is reacted with an oxidizing agent selected from the group consisting of sodium periodate (NaIO₄). and potassium perruthenate (KRuO₄).
64. The method of any one of claims 58-63, wherein steps (b) and (c) are performed consecutively in the same reaction vessel without isolation of the Schiff base formed in step (b).
65. The method of any one of claims 58-64, wherein the primary' amine catalyst is an aniline derivative.91185193632.
166. The method of any one of claims 58-64, wherein the primary amine catalyst is selected from the group consisting of benzamide, phenylene diamine, o-toluidine, m-toluidine. p-toluidine, o-anisidine, m-anisidine, and p-anisidine.92185193632.1
